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The uracil nucleobase plays a central role in the innate immune response against HIV-1 
infection in resting immune cells when it is found in DNA rather than RNA. The most 
well  characterized  uracil-centric  innate  immune  response  involves  host  DNA  cytidine 
deaminase enzymes (APOBECs), which selectively deaminate cytosine residues during 
HIV-1 first strand DNA synthesis thereby rendering the viral genome nonfunctional by 
Gà A hypermutation. Previous work from our group suggested the presence of another 
uracil-dependent  HIV-1  restriction  pathway  that  does  not  involve  APOBEC  enzymes. 
The function of this pathway, which has been historically controversial, involves 
incorporation of dUTP into viral DNA by reverse transcriptase to produce non-mutagenic 
U/A  base  pairs  (uracilation),  which  preserve  the  coding  potential  of  native  T/A  pairs. 
Notably, U/A pairs are “invisible” to normal DNA sequencing methods and their 
presence,  persistence  and  ultimate  fate  in  proviral  DNA  of  HIV-1  infected  cells  is  an 
important aspect of viral infection that has been largely unexplored. The limiting dNTP 
pool  levels,  high  dUTP  levels  and  unique  DNA  repair  capacities  of  non-dividing  cells 
such  as  monocytes,  macrophages  and  dendritic  cells  provides  a  unique  and  poorly 
understood metabolic environment for HIV-1 replication and infection.  
This  work  describes  new  methods  for  detecting  uracil  bases  in  HIV-1  DNA  and 
provides a detailed examination of their fate over the course of infection in monocyte-
derived macrophage (MDM) target cells of HIV-1. We report that a major subpopulation 
of MDMs has a metabolic phenotype leading to high levels of dUTP incorporation (U/A 
pairs) into HIV-1 DNA during reverse transcription. Importantly, ex vivo analysis showed 
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U/A base pairs are present in short-lived blood monocytes and alveolar macrophages (but 
not CD4+ T cells) from antiretroviral therapy (ART)-suppressed HIV-1 infected 
individuals suggesting that they arise from recent passage of monocytes through a drug 
resistant  viral  reservoir.  This  newly  defined  interplay  between  host  dNTP  pools,  DNA 
repair  machinery  and  HIV-1  is  important  for  understanding  the  potential  of  tissue 
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Sources of uracil in DNA 
The nucleobase uracil is a natural base of RNA but is often found in DNA through 
two parallel pathways that include cytosine deamination (spontaneous or enzyme 
catalyzed)  or  misincorporation  of  deoxyuridine  5’-triphosphate  (dUTP)  during  DNA 
replication.    Uracil  constitutes  the  most  common  lesion  in  genomic  DNA1,  and  if  not 
repaired,  deaminated  cytosine  residues  are  inherently  mutagenic  where  the  initial  U/G 
mispair results in C/G à T/A transition mutations upon DNA replication 2. In contrast to 
cytosine deamination, the generation of U/A base pairs is not inherently mutagenic but 
the  presence  of  uracil  may  be  sensed  as  a  cytotoxic  lesion  or  a  mutagenic  event  when 
chromosomal abasic (AP) sites are generated by the removal of uracils. Cellular 
organisms have evolved several universal DNA repair mechanisms to sense and remove 
these  lesions  to  preserve  the  integrity  of  their  genome.  However,  the  introduction  of 
uracil  in  viral  genomic  DNA  intermediates  during  synthesis  has  become  an  important 
component of the host innate immune response against invading viruses 3. Consequently, 
viruses  have  developed  several  important  strategies  to  prevent  the  incorporation  and 
persistence of uracil bases in their genome. 
 
Purposeful introduction of uracil APOBEC-mediated cytidine deamination 
The deamination of cytosine to uracil in DNA can arise spontaneously or 
enzymatically by APOBEC cytidine deaminases, which catalyze the irreversible 
hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, 
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respectfully3. The apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) 
enzyme family is capable of deaminating cytosines within DNA or RNA. Some members 
of  this  cytidine  deaminase  family,  including  activation-induced  cytidine  deaminase  or 
AID  are  expressed  exclusively  in  activated  B  lymphocytes  and  are  a  key  factor  for 
antibody  diversification4.  AID  targets  single  stranded  DNA  (ssDNA)  of  variable  and 
switch regions of the host-immunoglobulin (Ig) gene locus, promoting somatic 
hypermutation and class-switch recombination processes that are critical for generating 
antibody diversity in response to antigens5.
Perhaps  the  most  notable  of  the  APOBEC3  sub-family  with  respect  to  HIV-1 
infection  is  APOBEC3G  (A3G),  which  is  a  potent  host  restriction  factor  that  impedes 
HIV-1  replication6.  Subsequently,  it  was  discovered  that  the  human  genome  encodes 
seven APOBEC3 proteins: APOBEC3A, A3B, A3C, A3DE, A3F, A3G and A3H 7. With 
the  exception  of  A3H,  all  other  members  have  been  shown  to  exhibit  some  level  of 
antiviral activity towards numerous retroviruses including HIV, SIV, MLV and HTLV. 
The antiviral activity of these APOBEC3 proteins operates through a cytidine deaminase 
‘editing’ mechanism of viral cDNA leading to lethal Gà A hypermutation in a 
dinucleotide  CC  or  TC  sequence  specific  context,  where  the  cytosine  base  in  bold  is 
deaminated8.    Aside  from  their  antiviral  effects,  APOBEC3  proteins  posses  several 
alternative functions including inhibitory effects on intracellular targets MusD, IAP, Ty1, 
LINE-1 and an ability to prevent propagation of mobile elements in their host genomes9.  
To counteract cytidine deaminase editing and protect its genome from uracilation, 
HIV-1 has evolved to encode the viral infectivity factor protein, Vif 10,11. Vif specifically 
targets APOBEC3G for proteasomal degradation, thus depleting APOBEC3G at the site 
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of  virion  budding  and  subsequent  incorporation  into  progeny  virus6.    Importantly,  all 
lentiviruses except EIAV encode a Vif protein, where the interaction between 
APOBEC3G and vif has co-evolved to be species specific11. Consistent with this 
assertion, APOBEC3 proteins from various species can be packaged in vitro by HIV-1, 
but only human APOBEC3G can be degraded by HIV-1 Vif.  
 
U/A base pairs arise from dUTP misincorporation 
The  common  RNA  base  uracil  (U)  may  be  substituted  for  thymine  (T)  in  DNA 
because dUTP readily pairs with adenine (A) during DNA replication resulting in U/A 
base pairs. Uracil-adenine base pairs may also arise from utilization of dUTP by 
retroviral reverse transcriptases (RTs) that do not readily discriminate between dUTP and 
TTP during DNA synthesis12. While the initial uracil incorporation event is non-
mutagenic (U/A pairs retain their coding potential), they may become mutagenic and lead 
to genomic instability and fragmentation when acted upon by the universal cellular DNA 
base excision repair machinery (BER)13.   
Incorporation  of  dUTP  during  DNA  replication  has  been  estimated  to  result  in 
~10,000 uracil residues per genome per day and represents the major source of uracil in 
DNA.  In  eukaryotes,  dUTP  is  synthesized  from  the  phosphorylation  of  dUDP,  arising 
from UDP generated by ribonucleotide reductase (RNR) or from the phosphorylation of 
dUMP,  which  is  an  important  intermediate  in  the  de  novo  nucleotide  biosynthesis  of 
TTP14.  Importantly,  this  constitutes  a  permanent  source  of  cellular  dUTP.  Given  that 
DNA polymerases from eukaryotes and viruses are not able to successfully discriminate 
from dUTP and TTP, the intracellular concentration and composition of deoxynucleotide 
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triphosphates (dNTPs) dictates the level and frequency of dUTP incorporation.  
Accordingly,  all  dividing  cells  express  deoxyuridine  triphosphate  hydrolase  (dUTPase) 
that serves to keep dUTP pool levels very small15,16.
 
Unbalanced dNTP pool levels in myeloid lineage cells 
The steady-state composition and concentration of dNTP pool levels in 
mammalian  cells  is  tightly  regulated  due  to  the  highly  mutagenic  effects  of  nucleotide 
pool  imbalances  in  dividing  cells 17  and  antiviral  restriction18,19.  Under  physiological 
conditions where dUTPase is highly expressed, the cellular concentration of dUTP and 
TTP are reported to be around 0.2 and 37 µM, respectively, thus the dUTP/TTP ratio is 
about 1/100 in dividing cells in order to prevent uracil incorporation during chromosomal 
DNA replication20. 
In  non-dividing  cells,  such  as  terminally  differentiated  macrophages  or  other 
myeloid lineage cells, cellular dNTP concentrations are 6-133 fold lower than a typical 
dividing cell and the dUTP/TTP ratio is about 60:1 21.  These cells maintain their low and 
unbalanced intracellular nucleotide pool levels through high expression levels of 
SAMHD1 dNTPase and limited expression of the deoxyuridine 5’-triphosphate 
nucleotide hydrolase (dUTPase).  Consequently, viruses such as HIV-1 that are able to 
replicate  in  such  an  adverse  dNTP-depleted  environment  have  a  high  probability  of 
incorporating dUTP during viral replication. Not surprising, viruses have evolved ways 





SAMHD1 mediated dNTP pool depletion in quiescent immune cells 
SAMHD1 dNTPase is a recently identified viral restriction factor that is highly 
expressed  in  resting  immune  cells 18.  Restriction  of  HSV-1  and  HIV-1  in  quiescent 
immune cells has been directly linked to the expression of SAMHD1 23. Aside form its 
role as a viral restriction factor, inherited mutations in SAMHD1 lead to the severe early-
onset  chronic  neuroinflammatory  disease,  Aicardi-Goutieres  disease  (AGS)24.  Several 
alternative or secondary enzymatic activities of SAMHD1 have been described, including 
single-stranded (ss) DNA and RNA binding properties 25,26. 
The primary and most well characterized antiviral restriction activity of SAMHD1 
is  the  non-specific  dNTP  triphosphohydrolase  activity  that  reduces  all  cellular  dNTPs, 
including dUTP, to nanomolar levels which starve viral reverse transcriptase machinery 
of its substrates (Fig. 1) 27. In the studies of this thesis, we defined the complex ordered-
essential dNTPase activation mechanism of SAMHD1 involving two classes of activator 
sites and the catalytic site 28. Briefly, occupation of the (A1) activator site by any guanine 
containing nucleotide (d)GTP led to dimer formation, while binding of any dNTP at the 
second activator (A2) and catalytic sites generated the catalytically competent tetramer. 
The unique allosteric regulation mechanism of SAMHD1 requires the coordinated 
binding of 12 nucleotides to generate the long-lived activated tetrameric species 28. Once 
formed, the tetramer shows profound hysteresis and can persist for many hours even after 
activating  nucleotides  have  been  removed  from  solution.  Presumably,  this  enzymatic 
property  of  SAMHD1  allows  it  to  deplete  nucleotides  down  to  a  level  that  would  be 
impossible  to  achieve  if  activating  nucleotide  binding  followed  a  simple  reversible 
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equilibrium.  We  have  demonstrated  that  the  dNTP  pool  depletion  brought  about  by 
SAMHD1 is a key factor in determinint the dUTP/dTTP ratio in quiescent immune cells. 
 
Cellular and viral strategies to counteract incorporated uracil 
Viruses have devised many strategies to prevent the emergence of uracilated viral 
genomes and eliminate uracils that have already been incorporated in to genomic DNA. 
Viruses that utilize a DNA intermediate during replication, such as poxvirus, herpesvirus 
and retroviruses encode their own viral dUTPase and/or uracil DNA glycosylase (UNG) 
to compensate for the low expression levels of these cellular enzymes in some immune 
cells29.  An  important  exception  is  HIV-1  that  successfully  replicates  in  non-dividing 
immune cells but does not encode dUTPase or UNG. 
As mentioned earlier, the depleted nucleotide metabolic environment of myeloid 
lineage cells leads to preferential utilization of dUTP instead of TTP across from adenine 
during reverse transcription. The dUTP pool levels are elevated due to the weak 
expression of dUTPase in myeloid cells 30,31.  This enzyme reduces intracellular dUTP by 
converting it to dUMP and inorganic pyrophosphate. Reductive methylation of dUMP by 
thymidylate synthase (TS) generates dTMP from dUMP, which is then phosphorylated to 
TTP. Thus, dUTPase reduces the relative dUTP/TTP ratio and provides dUMP for the de 
novo  pathway  for  TTP  biosynthesis.  Through  alternative  splicing,  the  human  dUTPase 
gene encodes a mitochondrial and nuclear localized isoform 32. Expression of the nuclear 
isoform is cell cycle regulated where the highest levels of expression is seen at S phase, 
while  nearly  undetectable  levels  are  observed  in  differentiated  and  non-dividing  cells, 
including macrophages33. 
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The  second  mechanism,  which  is  responsible  for  removal  of  uracil  once  it  is 
incorporated  into  DNA,  is  uracil  base  excision  repair  (UBER).  UBER  is  the  primary 
mechanism used to remove uracil from DNA, and is initiated by the enzyme uracil DNA 
glycosylase (UNG). UNG activity produces an abasic (AP) site product, which is further 
processed by apurinic/apyrimidinic endonuclease 1 or 2 (APE1, APE2) 34. The resultant 
free 3’-OH and 5’-deoxyribose phosphate (dRP) are acted upon by the lyase activity of 
DNA  polyermase  β  (pol  β)  for  the  short  patch  repair  pathway.  Alternatively,  a  short 
oligonucleotide  is  cleaved  by  the  flap  endonuclease  1  (FEN1)  in  the  long  patch  repair 
pathway.  Finally,  the  resulting  gap  can  be  filled  in  by  polyermases  pol  β,  δ  or  ε  and 
ligated  by  ligase  I  or  III35.    DNA  glycosylases  involved  in  uracil  removal  are  highly 
conserved in mammals, bacteria, yeast and the viruses mentioned previously. 
Like dUTPase, the ung gene codes for both a mitochondrial (UNG1) and nuclear 
(UNG2) localized isoform through alternative splicing. UNG2 has been reported by many 
groups to be the DNA glycosylase solely responsible for the removal of misincorporated 
dUTP  in  the  form  or  U/A  base  pairs 36.  Nuclear  hUNG2  is  differentially  expressed 
through the cell cycle, it peaks at S phase in dividing cells and shows limited expression 
levels in non-dividing cells 37. Studies performed in mice and humans demonstrate that a 
UNG deficiency leads to accumulation of genomic uracils, confirming its role in removal 
of uracil in DNA38.
An analysis of primate lentiviruses (including HIV-1) demonstrated that they do 
not encode dUTPase or UNG-like enzymes yet are still capable of productively infecting 
macrophages and other non-dividing cells. The ability of these quiescent immune cells to 
support HIV-1 replication has led to several reports, although controversial, that suggest 
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viral packaging of host UNG2 into nascent virions 39. The hypothesis was first supported 
by a yeast two hybrid study that discovered viral protein Vpr bound to the C-terminus of 
UNG40. This interaction appeared to be dependent on Vpr’s ability to interact with the 
WxxF  motif  contained  in  UNG241.  Although  Vpr  was  initially  suspected  to  play  an 
important  role  in  packaging  of  hUNG2,  many  groups  have  since  reported  that  viral 
packaging  of  hUNG2  is  independent  of  Vpr 42.  While  it  has  been  shown  that  Vpr 
participates in reverse transcriptase fidelity, suggesting it may target hUNG2 to the viral 
replication  complex,  the  role  of  a  Vpr-hUNG2  complex  remains  to  be  conclusively 
discerned. Future experiments to further understand the function of a potential Vpr-UNG 
complex need to address several important parameters before a definitive conclusion can 
be  made.  These  parameters  include  the  use  of  a  relevant  physiological  cell  system, 
quantitative measures of hUNG2, dNTP pool levels, and the protection of uracilated HIV 
DNA from uracil excision in the absence of virally packaged hUNG2. 
 
General aspects of HIV-1 infection 
 Human  immunodeficiency  virus  type  1  (HIV-1)  is  responsible  for  the  acquired 
immunodeficiency  syndrome  (AIDS)  that  has  infected  close  to  40  million  individuals 
worldwide, primarily in sub-Saharan Africa, and has killed nearly half of them 43. HIV-1 
infection  of  CD4+  T  cells,  tissue  macrophages,  and  dendritic  cells  in  the  absence  of 
antiretroviral therapy (ART) leads almost undoubtedly to AIDS and death by 
opportunistic infections. The advent and introduction of ART has dramatically subverted 
this deadly scenario, however, the penetration of antiretroviral agents in both lymphoid 
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and non-lymphoid tissues is not always optimal, which leads to incomplete suppression 
of viral replication and possible selection of drug-resistant viral variants44. 
 HIV-1 infects cells through interaction of its gp120 envelope (Env) protein with 
the primary entry receptor CD4 molecule and one of two chemokine coreceptors (CCR5 
in  the  initial  phase  of  infection,  or  CXCR4  in  late-stage  disease)45  dualtropic  R5X4 
viruses are also known to exist46 Consequently, these entry receptors restrict the spectrum 
of target cells that HIV-1 can infect to CD4+ T lymphocytes (whose depletion in patients 
is  a  hallmark  of  AIDS)  and  to  mononuclear  phagocytes  (monocytes,  macrophages, 
microglial and myeloid dendritic cells)47. 
 Once  in  the  target  cell,  both  viral  and  cellular  proteins  form  a  pre-integration 
complex (PIC) that shuttles the viral genome to the host cell nucleus. The PIC interacts 
with  components  of  the  nuclear  pore  while  reverse  transcription  of  the  viral  RNA  into 
DNA is occurring. In the nucleus, viral integrase promotes the integration of linear forms 
of  proviral  DNA  in  to  host  chromosomes48.  At  the  proviral  stage,  HIV-1  will  remain 
stably associated within the host cell, whereas the expression of viral RNA and proteins 
will depend on the interplay of its own regulatory proteins and host transcription factors. 
The newly synthesized structural viral proteins along with many accessory proteins will 
assemble at the plasma membrane along with full-length viral genomic RNA to produce 
new progeny virions. 
The HIV life cycle has presented a rich source of targets for antiretroviral agents, 
which are typically delivered in combination during antiretroviral therapy (ART) 49.  ART 
has  significantly  prolonged  the  lives  of  many  patients  by  effectively  controlling  viral 
replication  over  the  entire  lifetime  of  the  patient 50.  However,  ART  has  not  been 
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successful  in  purging  or  preventing  the  formation  of  a  reservoir  of  infected  cells  that 
become  established  early  during  primary  HIV-1  infection.  Although  infrequent,  and 
relatively low in numbers, these cells carry integrated, replication-competent proviruses 
capable of reinitiating viral reemergence and disease progression if therapy is 
interrupted51.  In  addition  to  this  obstacle,  differentiated  tissue  macrophages  have  the 
unusual feature of being able to bud out virus into the extracellular milieu like CD4+ T 
cells, but also in subcellular compartments recently defined as virus-containing 
compartments (VCCs) 52,53. This functional feature leads to the possibility that 
macrophages could harbor long-lived reservoir of infectious virus that could be released 
upon cell death or physiological stimulation.
 
HIV-1 persistence in the monocyte-macrophage lineage 
Multiple mechanisms are likely to contribute to HIV persistence during long-term 
antiretroviral therapy. A vast majority of CD4+ T cells that are productively infected are 
likely  to  die  from  virus-induced  cytopathic  effects,  but  a  small  subset  of  long-lived 
resting memory T cells that harbor integrated HIV DNA known to persist indefinitely, 
which is generally referred to as latency 54. Memory CD4+ T cells are the largest and best 
characterized cellular reservoir in humans. The presence of latent proviral HIV-1 DNA in 
this cell population has been unambiguously proven 55. Genetic studies have shown that 
during viral rebound after interrupted ART the virus could be detected from an additional 
distinct  reservoir56.  One  possibility  is  that  latent  HIV  infection  may  also  occur  in  cell 
populations other than memory T cells, including cells from the monocyte-macrophage 
lineage (Fig. 1.2).
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Cells of the myeloid lineage may also play an important role in controlling and 
propagating the initial infection and therefore contribute to the general establishment of 
viral  reservoirs,  because  these  cells  are  involved  in  a  wide  range  of  both  innate  and 
adaptive  immune  functions.  In  support  of  a  contribution  from  myeloid  lineage  cells  in 
viral persistence after ART, infected monocytes have been recovered from the blood of 
HIV-1 infected individuals, even from those on ART with undetectable viral loads 57-59. 
Many studies have shown that monocytes harbor proviral HIV-1 DNA 60-62 Ellery et al. 
suggested that a minor monocyte sub-population (CD16++) is more permissive to 
infection  than  the  more  abundant  CD14 ++CD16-  monocyte  subset 63.  In  ART  naïve 
patients,  HIV-1  proviral  DNA  is  detected  at  very  low  levels  (between  0.01-1%)  in 
circulating monocytes, while CD4+ T cells likely contribute over 99% of viral particles. 
In this situation, viruses produced by blood monocytes may be too minor to recognize. 
However,  in  patients  on  suppressive  ART  where  HIV  replication  in  CD4+  T  cells  is 
blocked, viruses released from monocytes may become a dominant factor. 
A physiologically relevant role for monocytes in HIV infection is supported by 
the observation that higher levels of HIV-1 transcripts and sequence evolution is 
observed in CD14+ monocytes than in resting CD4+ T cells of patients on ART 60. This 
finding  suggests  a  higher  level  of  HIV-1  replication  in  monocytes  compared  to  resting 
CD4+ T cells. Importantly, HIV-infected circulating blood monocytes may serve as an 
indirect source of HIV-1 by carrying virus in the circulation and then differentiating into 
tissue  macrophages  where  HIV  may  replicate  for  long  periods  due  to  the  resistance  of 
macrophages  to  viral  induced  apoptosis  (Trojan  horse  hypothesis) 64.  Given  their  short 
half-life in peripheral blood (1-3 days) prior to differentiating in to macrophages 65, the 
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finding of persistent HIV-1 proviruses in blood monocytes suggests they were recently 
infected  by  passage  through  a  tissue  reservoir.  Thus,  ongoing  renewal  of  an  infected 
monocyte/macrophage pool may be important for seeding HIV-1 into sanctuary sites in 
various tissues. 
 Macrophages are myeloid lineage cells of the innate immune system that can be 
found in virtually every tissue of the body and are responsible for myriad of functions, 
from tissue homeostasis and repair to recognition and destruction of invading pathogens 
and tumor cells 50,66. Macrophages originate from either primitive embryonic precursors 
or  from  infiltrating  bone  stem  cell-derived  monocytes,  leading  to  monocyte-derived 
macrophages (MDMs)67. In vitro derived MDMs are the most common surrogate model 
of  tissue  macrophage  physiopathology,  including  HIV-1  infection67.  The  function  and 
phenotype  of  MDMs  differ  widely  between  and  within  tissues,  which  has  important 
implications  in  normal  physiology  and  disease  such  as  HIV-1.  HIV-1  infection  of 
macrophages was first described in the 1980s from ex vivo analysis of tissues from post 
mortem  AIDS  patients 68.  Originally  a  high  frequency  of  infected  macrophages  was 
observed in brain, lung and secondary lymphoid tissue 69. However, recent studies have 
shown infected macrophages in many tissues at all stages of disease, which persist under 
ART70,71. The in vivo morphological features of infected macrophages of AIDS patients 
are  recapitulated  by  in  vitro  infection  of  human  MDMs  with  macrophage-tropic  viral 
strains suggesting that MDMs are a reasonable model system for understanding in vivo 
HIV infection of macrophages 72. 
Given the difficulty in accessing relevant tissues, the role that macrophages and 
other myeloid cells play in shaping and maintaining the viral reservoir has been difficult 
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to  discern.  Accordingly,  research  efforts  have  focused  on  accessible  tissue  reservoirs 
where most of the virus is thought to reside, particularly where there are dense collections 
of target cells that might support cell-to-cell transfer of virus73 Specifically, 
understanding the role of macrophages as a viral reservoir and the way in which signaling 
between myeloid cells and CD4+ T cells leads to HIV persistence have become critically 
important.
 
Macrophages and viral pathogenesis 
Despite the successes of ART, standard therapies do not fully restore health or a 
normal  immune  status  in  HIV  infected  individuals  and  patients  still  experience  co-
morbidities, including increased cognitive impairment, cardiovascular disease, and bone 
disorders74. In addition to their role in the spread and persistence of HIV-1, infection of 
macrophages  may  be  directly  involved  in  promoting  disease  through  the  activation  of 
inflammatory  processes.  Consistent  with  this  assertion,  HIV-1  infection  of  the  central 
nervous  system  (CNS)  is  widely  associated  with  inflammation  leading  to  pathology 
ranging from encephalitis to mild but progressive congestive dysfunction, associated with 
neuronal death75. Although ART generally reduces the burden of CNS disease, low levels 
of residual inflammation resulting from persistent infection of resident macrophages may 
continue to cause progressive disease.
Both respiratory and bowel dysfunction have been associated with HIV-1 
infection.  Impaired  macrophage  function  has  been  implicated  in  lower  respiratory  tract 
infections  as  evidenced  by  the  fact  that  HIV-1  infected  alveolar  macrophages  have 
reduced phagocytic activity both in ART-suppressed and naïve donors 76. HIV-1 infection 
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of  the  gut-associated  lymphoid  tissue  (GALT)  results  in  damage  to  the  immunological 
and  physical  barriers,  which  can  lead  to  microbial  translocation  promoting  chronic 
immune activation 77. Given that monocytes are recruited by inflammation to the site of 
tissue damage and also polarize these incoming cells according to the local environment, 
this would lead to amplification of ongoing inflammatory processes in the GALT.
Any local or global inflammation associated with HIV-1 infection is a serious risk 
factor for cardiovascular disease (CVD) and macrophages are proposed to play a central 
role in CVD pathogenesis. Human trials have revealed correlations between duration of 
HIV-1 infection, markers of inflammation, the presence of inflammatory macrophages in 
the vasculature and CVD57.  A recent study with implications for both reservoir formation 
and pathogenesis of osteolytic bone disease is the infection of osteoclasts in both ART-
suppressed and naïve donors. Osteoclasts are myeloid lineage cells that can be derived in 
vitro from blood monocytes, express CD4 and CCR5 and are readily infected by HIV-1 78. 
These infected osteoclasts upregulate markers of activation and increased bone resorption 
activity, suggesting a direct role in bone disease.
 
Barriers to viral eradication and a cure for HIV-1 
Despite the advent and effectiveness of ART, the ability for HIV-1 to establish 
latent infection remains the key obstacle to viral eradication and a cure for HIV-1. If ART 
therapy  is  discontinued,  even  after  years  of  viral  suppression,  latently  infected  cellular 
reservoirs  become  reactivated  leading  to  viral  rebound.  These  cellular  reservoirs  are 
dormant,  long-lived  cells  that  harbor  replication-competent  viruses  that  evade  immune 
detection because viral proteins are expressed very infrequently or not at all 79. Most of 
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the attention in this regard has focused on CD4+ T cell reservoirs in which the virus can 
reside in a latent state that will be difficult to eliminate. While the majority of research 
has focused on CD4+ T cells as the primary cellular reservoir of HIV, there is evidence to 
support  other  sites  as  potential  cellular  or  anatomical  reservoirs,  including  (GALT), 
peripheral blood, bone marrow, and the brain.  
Macrophages  are  infected  in  vivo  in  a  tissue-specific  manner.  GALT  has  long 
been associated with HIV-1 infection and is abundant in macrophages 80. Ex vivo analysis 
of  human  GALT  macrophages  showed  that  they  are  relatively  refractory  to  infection 
compared to MDMs, and this phenotype was supported by exposure of MDMs to TGFβ, 
which down regulated CD4 and CCR5 expression and inhibited viral infection 81. Despite 
the  comparative  refractory  nature  of  GALT  macrophages  to  infection,  HIV-1  has  been 
detected in macrophages from human duodenum tissues from ART-suppressed donors 80. 
Further,  macrophages  that  were  proximal  to  the  rectum  exhibited  increased  CCR5 
expression  and  also  enhanced  HIV-1  susceptibility  compared  to  colon-resident  cells, 
reinforcing  the  importance  of  the  tissue-specific  macrophage  phenotype  in  infection. 
Given  that  CCR5  directly  mediates  macrophages  susceptibility  to  HIV-1,  its  increased 
expression through the clinical course of infection suggests a greater role for 
macrophages in advanced stages of disease82,83.
The brain has been recognized as an organ target for HIV-1 macrophage infection 
since the 1980’s. The principal target cells in the brain are the microglia and perivascular 
macrophages,  which  are  infected  rapidly  after  transmission,  although  the  source  of 
infecting virus is unclear 84,85. While access to the human CNS during acute infection is 
prohibitively challenging due to the blood-brain barrier, it seems likely that once infected, 
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the CNS will remain so for the lifetime of the host, implying that this is an important viral 
reservoir75. Consistent with this assertion, recent work has shown that genetically distinct 
HIV-1 variants exist in the CNS and plasma, and importantly, viral RNA can be detected 
in the CSF of ART-suppressed donors when viral RNA is undetectable in the plasma 56.
Aside from the CNS, the majority of the limited amount of information on HIV-1 
infection of human tissue macrophages has been derived from few anatomic sites that are 
accessible with minimally invasive procedures. On accessible site is lung alveolar 
macrophages, obtained from bronchioalveolar lavage (BAL) 86. These are targets of HIV-
1  with  important  implications  for  local  tissue  damage  and  viral  reservoir  formation. 
Fluorescence  in  situ  hybridization  (FISH)  revealed  macrophages  transcribing  HIV-1  in 
small  alveolar  macrophages76.  A  study  involving  ART-suppressed  donors,  showed  that 
while  most  of  the  patients  analyzed  had  undetectable  plasma  viral  loads,  (16/23)  had 
detectable proviral HIV-1 DNA in alveolar macrophages, of which eight had measureable 
viral  RNA77.  Again,  compartmentalization  of  HIV  infection  within  the  lung  of  ART-
treated donors is strong evidence that this tissue may well be an important persistent viral 
reservoir. 
As  the  HIV  research  field  investigates  strategies  to  eliminate  cellular  reservoirs 
that  persist,  even  during  aggressive  ART  therapy,  the  nature  of  the  cellular  and  tissue 
reservoirs  that  sustain  viral  persistence  becomes  an  important  question.  Central  to  this 
question  and  the  role  that  resident  macrophages  may  play  in  viral  eradication  is  the 
significance of their compartmentalization in drug-resistant tissues. While ART has been 
extremely successful in preventing disease progression, primarily through preservation of 
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the  CD4+  T  cell  population,  many  of  these  drugs  have  low  penetrance  and  are  not 
maintained at high levels in many tissue sub-compartments harboring macrophages87. 
Given that macrophages are long-lived and can support ongoing viral replication 
in  drug-resistant  tissues  warrants  additional  attention.  The  persistence  of  intracellular 
HIV-1 in sanctuary sites such as the CNS, where the penetration of some antiviral drugs 
is restricted by the blood-brain barrier, is considered a relevant obstacle to the treatment-
induced  elimination  of  infection.  Several  studies  have  demonstrated  that  viral  protease 
and reverse transcriptase inhibitors are less effective in chronically infected macrophages 
compared to CD4+ T cells 21. This reinforces the hypothesis that mononuclear phagocytes 
as well as microglia could accumulate infectious virus, which would remain invisible to 
immune  recognition,  while  virus  production  at  these  sites  could  be  less  affected  by 
systemic administration of antiretroviral agents. 
 
A hidden HIV-1 restriction and persistence mechanism in macrophages 
Previous  reports  on  the  role  of  viral  DNA  uracilation,  host  uracil  base  excision 
repair and HIV-1 infection of resting immune cells have been inconsistent and 
controversial [reviewed in 50]. In the studies described here, we evaluated the mechanism 
by  which  uracils  are  introduced  in  viral  DNA  of  MDMs  and  explored  the  biological 
consequences.  We  now  report  the  basic  elements  of  a  restriction/persistence  pathway 
involving  incorporation  of  dUTP  into  HIV  DNA  and  their  excision  by  the  host  UBER 
pathway of infected MDMs (Fig. 1.3). Surprisingly, this pathway only operates in a sub-
set of myeloid lineage cells and not in activated or resting CD4+ T cells.
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We have found that monocyte-derived macrophages (MDMs) consist of two sub-
populations of cells distinguished by their ability to express GFP upon infection with a 
GFP-containing reporter virus. The GFP - sub-population contains high dUTP levels and 
uracilated viral DNA products after infection, whereas viral DNA products in the GFP + 
sub-population do not contain.  
The  fundamental  biochemical  characteristic  of  the  GFP -  sub-population  relevant  to 
uracilation is their elevated dUTP/TTP level. This phenotype is brought about by their 
high expression levels of SAMHD1 dNTPase and by their low or undetectable dUTPase 
activity. Although GFP + macrophages and CD4+ T cells also share high expression levels 
of SAMHD1, they both exhibit higher expression of dUTPase, which depletes the dUTP 
pool and precludes the uracilation phenotype.   
 
Impact of UBER on virus reemergence and sequence diversification  
We estimate, based on comparing the measured levels of early and proviral DNA 
levels in the GFP- MDMs, that ~99% of the viral DNA is destroyed before the integration 
step. The viral DNA products that escape initial restriction can faithfully integrate into 
the host cell DNA with similar efficiency as non-uracilated DNA. Uracilated proviruses 
can then persist as U/A pairs, undergo faithful repair by UBER to yield normal T/A base 
pairs, or suffer error-prone repair resulting in viral mutagnesis or abortive infection. RNA 
pol II, not reverse transcriptase, appears to be the primary source of viral mutagenesis in 
infected  MDMs.  The  mutational  frequency  can  be  augmented  by  the  pro-inflammatory 
(M1)  cytokine,  IFNγ,  while  the  anti-inflammatory  (M2)  IL-2  appears  to  significantly 
reduce  viral  mutagenesis.  The  combination  of  transcription-coupled  repair  and  RNA 
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polymerase II associated errors may play an important role in viral evolution in 
macrophages independent of reverse transcription.  
 
Use uracil to elucidate target cellular reservoirs of HIV-1  
 We  have  detected  U/A  base  pairs  in  short-lived  blood  monocytes  from  ART-
suppressed  HIV  infected  individuals  suggesting  that  they  arise  from  recent  passage  of 
monocytes  through  a  drug  resistant  viral  reservoir.  This  work  may  help  define  a  more 
precise  description  of  where  the  virus  exists  during  effective  therapy  and  how  these 
reservoirs acquire HIV. Interestingly, on top of the genetic aspects of U/A pairs is their 
potential to down regulate gene expression through epigenetic silencing 88, which could 
allow transcriptionally silenced proviruses to endure and participate in the establishment 
and persistence of infection. Uracilation of viral DNA may define a new mechanism that 
maintains  viral  quiescence  in  persistently  infected  cells.  Knowledge  about  pathways 
leading  to  uracil  incorporation  and  persistence  may  provide  needed  insights  into  how 
latency  is  established  and  maintained,  and  might  lead  to  the  development  of  new 








Figure  1.1:  Diverse  roles  for  SAMHD1.  (A)  Non-specific  dNTP  triphosphohydrolase 
activity of SAMHD1 reduces all dNTPs to the deoxynucleoside and inorganic 
tripolyphosphate. (B) Involvement of SAMHD1 in innate and adaptive immune 


















Figure 1.2: Cellular targets of HIV-1 (A). Latent HIV infection can be established in T 
cell and myeloid cell reservoirs. All cells from the monocyte-macrophage lineage appear 
to  derive  from  a  same  progenitor  multipotent  cell,  the  hematopoietic  stem  cell  (HSC). 
(B). The HSC, located in the bone marrow, may differentiate either into a myeloid or a 
lymphoid precursor, setting up the divergence between the myeloid (blue) and 
plasmacytoid  (green)  lineage.  The  myeloid  precursor  is  then  able  to  migrate  into  the 
blood stream and differentiate into a monocyte. Depending to the location, the monocytes 
become either interstitial dendritic cells, macrophages or microglial cells. (Adapted from 









lineage  cells.  (A).  The  unique  nucleotide  metabolic  environment  (low  expression  of 
dUTPase  and  high  SAMHD1)  in  monocytes  and  macrophages  leads  to  the  preferential 
incorporation  of  dUTP  in  viral  cDNA.  Modest  UNG2  expression  levels  in  these  cells 
promote the survival and persistence of uracilated viral DNA.  (B) Depletion of dUTP 
through  high  levels  of  dUTPase  is  the  major  barrier  excluding  dUTP  incorporation. 
Robust levels of nuclear localized UNG2 results in extensive damage and fragmentation 
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Chapter 2: GTP activator and dNTP substrates of HIV-1 restriction factor 
SAMHD1 generate a long-lived activated state 
This chapter has been reproduced, with modification, from Hansen E.C., Seamon K.J., 
Cravens S.L., Stivers J.T. Proc. Natl. Acad. Sci. U.S.A. 2014;111:E1843-E1851. 
(http://www.pnas.org/content/111/18/E1843.full) 
◦  
◦ Introduction  
The steady-state composition and concentration of deoxynucleotide triphosphate pools in 
mammalian cells are highly regulated because of the mutagenic consequences of dNTP 
imbalances in dividing cells (1, 2) as well as the important antiviral effects of dNTP pool 
depletion in quiescent cells (3, 4). In all cell types, the ultimate pool balance is 
determined by dNTP-dependent regulatory pathways that affect the activities of enzymes 
involved in both synthesis and degradation of dNTPs (5–7). The most important highly 
up-regulated synthetic enzyme during S phase of dividing cells is the R1/R2 isoform of 
ribonucleotide triphosphate reductase, which ensures that dNTP precursors are plentiful 
for DNA synthesis (8). However, in quiescent cells of the immune system (resting CD4+ 
T cells, macrophages, and dendritic cells), where dNTP pools are ∼10-fold lower than 
dividing cells, the ultimate pool levels are likely determined by a balance between the 
activities of the R1/p53R2 isoform of ribonucleotide triphosphate reductase and the 
degradative dNTP triphosphohydrolase sterile α-motif/histidineaspartate domain-
containing protein 1 (SAMHD1) (9). The highly dynamic nature of dNTP pools demands 
finely tuned mechanisms for feedback regulation of these enzymes by dNTPs as well as 
coarse regulatory mechanisms (posttranslational modifications, transcriptional regulation, 
and proteasomal targeting) that serve to turn these activities on and off at appropriate 
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stages of the cell cycle and in specific cell types (10, 11). dNTP triphosphohydrolase 
enzymes, such as SAMHD1, are conserved from bacteria to humans and carry out the 
unusual conversion of dNTPs to the nucleoside (dN) and tripolyphosphate (12, 13). The 
tripolyphosphate is likely degraded to 3Pi through the action of plentiful cellular 
pyrophosphatases or tripolyphosphatases (14). Presumably, degradation to the level of 
nucleoside rather than deoxynucleoside diphosphate (dNDP) or deoxynucleoside 
monophosphate (dNMP) is to make the process energetically or kinetically costly to 
reverse, with the additional possibility that the neutral nucleoside will be irreversibly 
transported out of the cell (9). The unusual triphosphohydrolase activity of SAMHD1 in 
quiescent immune cells has received significant attention, because HIV-1 and HSV-1 are 
severely restricted in their ability to infect quiescent cells that have severely depressed 
dNTP pools, which has been directly linked to SAMHD1 enzymatic activity (15, 16). 
Mutations in the SAMHD1 gene have also been linked to Aicardi–Goutières syndrome, a 
rare genetic autoimmune encephalopathy with a chronic inflammatory pathology that 
resembles congenital viral infections (17). As would be expected, resting CD4+ T cells 
from Aicardi–Goutières syndrome patients are permissive to HIV-1 infection (18). A key 
question with SAMHD1 is how its activity is tuned in response to dNTP pool levels. 
Early reports established that the dNTPase activity of SAMHD1 required the presence of 
dGTP as an activator when dATP, dTTP, or dCTP was used as a substrate (15, 17). 
Subsequently, it was reported that the dGTP activator/ substrate can be replaced by GTP, 
which serves as an activator, but not a substrate (19). Two recent structures of SAMHD1 
in complex with dNTPs show a tetrameric quaternary structure with dGTP molecules 
bound to the (A1A2)4 activator sites and one dNTP bound to each of four catalytic sites 
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(20). Comparison with an earlier dimeric structure of the free enzyme suggests that 
activator and/or substrate binding drive the enzyme into the tetrameric form (15, 21). The 
importance of this enzyme in innate immunity (15), autoimmunity (17), and control of 
the transition from G1 to S phase in the cell cycle (5) makes an understanding of its 
regulatory and catalytic mechanism of interest. In addition, such mechanistic work can 
also provide useful insights to guide the design of mechanism-based activators and 
inhibitors of SAMHD1 that could have research or therapeutic uses. In this study, we 
have characterized the coordinated effects of activator and substrate binding on 
oligomerization and activation of the enzyme and discovered a long-lived activated state 
of SAMHD1 that is not in equilibrium with free activator nucleotides. We propose that 
GTP combined with any dNTP serve as the preferred activators for SAMHD1 in the cell 
and that the long-lived activated state is key for efficient dNTP depletion. 
 
 
Materials and Methods 
SAMHD1  Enzyme  Cloning  and  Overexpression.  SAMHD1  full  length  (1881  bp) 
construct was PCR amplified using the forward primer (Full length; 5’-
GTAACTCATATGCAGCGAGCCGATTCC-3’, and the reverse primer 5’-
GCACCTGGATCCCTACATTGGGTCATCTTT-3’) from the cloned full length cDNA 
vector from the Invitrogen Ultimate ORF collection (clone IOH55544). SAMHD1 gene 
was  ligated  into  a  pET19b-His10-PPS  (Novagen)  plasmid  (Nde1  and  BamH1)  and  the 
sequence  was  confirmed  by  sequencing  both  DNA  strands.  Full  length  construct  was 
expressed as a N-terminal His10-PPS fusion.  Escherichia coli BL21-DE3 cells (Novagen) 
were transformed with the pET19b-His10-PPS plasmid and grown in LB medium at 37°C. 
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Once  an  OD600  =  0.5  was  achieved  the  temperature  was  reduced  to  16°C  on  ice. 
Expression  was  induced  by  addition  of  0.25  mM  IPTG.  After  expression  for  24  h  at 
16°C, cells were harvested via centrifugation (4,000 x g) and frozen at -80°C. Cells were 
resuspended in lysis buffer containing [50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM 
EDTA,  0.1%  Triton  X-100,  10%  glycerol]  and  one  protease  inhibitor  cocktail  tablet 
(Sigma).  Cells  were  lysed  by  addition  of  0.5  mg/mL  hen  egg  white  lysozyme.  The 
resulting cell lysate was clarified via centrifugation (30,000 x g), filtered with a 0.2 µm 
syringe  top  filter  and  loaded  onto  10  ml  of  Ni-NTA  resin  (Qiagen)  that  had  been 
equilibrated in buffer A [50 mM Tris-HCl (pH 7.5), 150 mM KCl, 5 mM MgCl 2, 1 mM 
DTT, 10% glycerol] at 4°C.  Unbound material was removed with 3 column volumes of 
buffer A supplemented with 50 mM imidazole and bound SAMHD1 protein was eluted 
using  a  linear  gradient  of  buffer  A  containing  0-100%  500  mM  imidazole.    Fractions 
containing SAMHD1 were pooled and incubated with PreScission protease (PPS) for 1 h 
at 4°C to remove N-terminal His 10 tag.  Crude protein was diluted 10-fold into buffer A 
[50 mM Tris-HCl (pH 7.0), 20 mM NaCl, 5 mM MgCl 2, 1 mM DTT, 10% glycerol] and 
loaded onto a SP-sepharose cation-exchange column (GE Healthcare). Bound protein was 
eluted with a 0-100% linear gradient of buffer A containing 500 mM NaCl.  Fractions 
containing protein were analyzed via SDS-PAGE and judged to be ~99% pure.  Purified 
proteins were buffer exchanged into storage buffer [50 mM Tris-HCl (pH 7.5), 150 mM 
KCl, 5 mM MgCl 2, 1 mM DTT and 10% glycerol] by chromatography using sephacryl 
200HR  gel  filtration  resin  (Sigma-Aldrich).  Protein  concentrations  were  determined  by 
absorbance  measurements  at  280  nm  using  the  calculated  (Protparam  tool,  ExPASy) 
molar extinction coefficients for full length human SAMHD1 monomer (ε = 76,500 M -1 
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cm-1).  Protein yields were typically 20 mg/L of bacterial culture.  Purified proteins were 
stored at -80°C in small portions. Experiments were initiated by thawing a single (20 µL) 
aliquot, stored at -20°C, and used over the course of three days before being discarded.  
Steady-State Kinetic Measurements. Standard reaction conditions for steady-state 
kinetic measurements were 0.01 to 5 mM GTP (activator), 50 mM Tris-HCl (pH 7.5), 50 
mM KCl, 5 mM MgCl 2, and 0.5 mM TCEP in a 12 µL total reaction volume at 22°C.  
Concentrations of the [5- 3H] dUTP or [8- 3H] dGTP substrates were varied in the range 
0.01 to 5 mM and standard reactions were initiated by the addition of SAMHD1.  Two 
microliter  samples  were  removed  at  indicated  times  and  quenched  by  spotting  onto  a 
C18-reversed phase thin layer chromatography (TLC) plate.  The TLC plate was 
developed in 50 mM KH 2PO4 (pH 4.0) to separate substrate [dGTP (R f = 0.80) or dUTP 
(Rf = 0.97)] from products [dG (R f = 0.20), dU (R f = 0.54)].  Plates were exposed to a 
tritium  sensitive  screen  for  5  h  and  then  scanned  on  a  Typhoon  phosphoimager  (GE 
Healthcare) and the counts present in the substrate and product were quantified using the 
program Quantity One (Bio-Rad).  The amount of product formed at each timepoint was 
calculated  from  the  ratio  (cpm  dN  product)/(cpm  dNTP  substrate  +  cpm  dN  product)  
(intial [dNTP]).  Initial rates of product formation were obtained from the slopes of linear 
plots of [dN] versus time at reaction extents of less than 20%.  The reaction rates (µM/s) 
were  plotted  versus  dNTP  substrate  concentration  at  various  concentrations  of  GTP 
activator  as  described.    For  GTP  activation  with  dUTP  as  the  substrate,  the  kinetic 
parameters were determined by fitting to an ordered essential activation mechanism (eq 
1),  where  [S]  is  dUTP,  [A]  is  GTP,  Km
app, dUTP is  the  apparent  Michaelis  constant  at  a 
given concentration of GTP activator, K act
app, GTP is the activation constant for GTP at a 
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given  [S],  and  Vmax
app, dUTP is  the  apparent  maximal  velocity  for  dUTP  hydrolysis  at  a 
given activator concentration.   
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Mechanism of Activation and Inhibition by dGTP.  dGTP is both a cis-activator and a 
substrate  and  sigmoidal  plots  of  velocity  versus  [dGTP]  would  be  expected.  However, 
sigmoidicity  was  not  observed  and  the  steady-state  velocity  data  in  the  presence  and 
absence of the trans-activator GTP were fitted to a simple hyperbolic expression (eq 1).  
To investigate the activation and inhibition of dUTP hydrolysis by dGTP, we used a fixed 
concentration  of  the  dUTP  substrate  (1  mM)  and  varying  concentrations  dGTP  in  the 
range  5  µM  to  5  mM.    These  data  were  fitted  to  the  mechanism  in  eqs  5-8  using 
numerical integration methods and nonlinear least squares optimization to the data (30). 
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dGTPαS: Inhibition, Activation and Reactivity.  Inhibition by dGTPαS was evaluated 
under reaction conditions containing SAMHD1 (0.5 µM), fixed dUTP (1 mM) substrate 
while varying the concentrations of dGTPαS (5 µM – 5 mM).  Since dGTP behaves both 
as  a  cis-activator  and  a  substrate,  we  presumed  that  dGTPαS  would  behave  similarly. 
Therefore,  the  data  were  fitted  by  simulation  to  the  mechanism  in  eqs  5-8  to  obtain 
Kact
dGTPαS  and Ki
dGTPαS.  
Dilution-Jump Kinetic Measurements.  In the standard assay SAMHD1 (10 µM) was 
incubated for 10 seconds with varying concentrations of GTP, dUTP, and/or dGTP prior 
to  a  100-fold  dilution  into  standard  reaction  buffer  containing  [5-3H]  dUTP  (1  mM).  
Time points were then quenched on a TLC plate and product formation was quantified as 
described above.  Plots of [dU] against time were fitted to the equation [dU] = A[1 - exp(-
kinactt)] + vt, where A is the burst amplitude (µM), k inact is the rate constant for the burst 
decay (s -1), and v is the linear steady-state rate (µM/s).  Variations of the standard assay 
were performed as indicated in the text. 
Dilution-Jump  Glutaraldehyde  Cross-linking.  The  standard  dilution-jump  procedure 
E + dGTP EdGTP
EdGTP + dUTP EdGTPdUTP
EdGTP + dGTP EdGTPdGTP










was performed except that samples from the diluted reactions were taken at various times 
and  mixed  with  50  mM  glutaraldehyde.  Samples  were  incubated  at  22°C  for  15  min, 
quenched by addition of 1 M Tris, pH 7.5 and loaded on to a 4-12% Bis-Tris denaturing 
polyacrylamide  gel.    Protein  samples  were  visualized  by  silver  staining.    Briefly,  gels 
were fixed overnight in a 50 mL solution containing 50% methanol, 10% acetic acid and 
0.02%  paraformaldehyde.  Gels  were  washed  three  times  for  20  min  in  20%  ethanol, 
followed by 5 min incubation in sensitizing solution containing 0.02% sodium 
thiosulfate.  Sensitizing  solution  was  removed  by  washing  twice  with  50  mL  of  ddH2O 
and immediately transferred to an equivalent volume of staining solution containing 0.2% 
silver nitrate and 0.03% paraformaldehyde. Finally, gels were developed for 2-5 min in a 
6% sodium carbonate, 0.02% paraformaldehyde (50 mL) solution. Developer was 
quenched by direct addition of an equivalent volume of 50% methanol and 10% acetic 
acid. Gels were imaged immediately using an Epson V750 flat-bed scanner. Quantitation 
of  monomer,  dimer  and  tetramer  populations  was  performed  using  Quantity-One  (Bio-
rad) software.  
Binding Stoichiometry and Kinetic Release of Activator Nucleotides. The binding of 
nucleotides was measured by mixing SAMHD1 (10 µM) with [γ-32P] GTP (0.5 mM) and 
[5-3H] dUTP (1 mM) in standard reaction buffer. This solution was immediately applied 
to a buffer-equilibrated Micro Bio-Spin P-30 gel filtration spin column (Bio-Rad) and the 
protein was eluted according to manufacturer instructions. After 2 min, the eluted protein 
was  filtered  through  a  second  Micro  Bio-Spin  P-30  column.  After  each  spin  step  the 
protein eluate was cross-linked with glutaraldehyde to quantify the percentage of 
tetrameric SAMHD1, as described above. The remaining solution present after the first 
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and second columns (50-60 µL) was added to 10 mL of scintillation fluid and 32P and 3H 
decays were counted using appropriate channel windows on a Beckman LS-6500 
Scintillation Counter. Control reactions without enzyme were run to determine 
background  from  unretained  nucleotides  (<1%).  The  recovery  of  SAMHD1  from  the 
column  was  96%.  After  correcting  for  the  background  and  the  protein  recovery,  the 
stoichiometry  of  bound  dUTP  and  GTP  per  monomer  subunit  of  tetrameric  SAMHD1 
was calculated.  
Analytical Ultracentrifugation.  Sedimentation velocity experiments were performed on 
a Beckman XL-I analytical ultracentrifuge equipped with an An-Ti 60 rotor and 
interference optics. All runs were performed at 50,000 rpm and 20°C with scans taken 
every 30 seconds for 9 hours. SAMHD1 protein samples were dialyzed overnight at 22°C 
against a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM KCl, 5 mM MgCl 2, 0.5 
mM DTT, and 5% glycerol. After loading the cells, the rotor was allowed to thermally 
equilibrate for 3 hours prior to the start of the run. SEDNTERP was used to determine 
partial  specific  volume,  density,  and  viscosity  of  the  protein  and  buffer  (31).  These 
parameters were then used in SEDFIT to fit the scan data to a c(S) distribution (32).  To 
determine  the  dissociation  constants  for  the  monomer-dimer  (KD)  and  dimer-tetramer 
equilibria (K T), scans at different concentrations were globally fit using SEDANAL by 
assigning an arbitrary slow dissociation rate constant of 10 -5 sec -1.  The 95% confidence 
intervals were determined from the integrated F-statistics module in SEDANAL (33). 
Computational  Modeling.  Structural  models  of  SAMHD1  bound  to  dUTP/GTP  and 
GTP/GTP  were  made  by  modification  of  the  crystal  structure  containing  tetrameric 
SAMHD1 bound to dGTP in both activator sites (PDB ID: 4MZ7).  The nucleobase and 
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sugar moieties were built using Discovery Studio (Accelrys) and then positioned into the 
allosteric  pockets  in  the  same  planes  and  configurations  as  the  original  ligands.    No 
further refinement of the dUTP structure was required.  However, the GTP/GTP ribose 
sugars  showed  steric  conflict  and  were  subjected  to  1000  cycles  of  steepest  descent 
energy  minimization  using  the  CHARMM27  molecular  dynamics  force  field  within 
HyperChem7 (HyperCube, Inc.) in an unsuccessful attempt to alleviate the steric clash. 
Visualization of the resultant structures was done using PyMOL. 
 
Results 
Activation of dUTP Hydrolysis by GTP.  The complex dGTP/GTP-dependent 
activation mechanism for dNTP hydrolysis and the possibility that SAMHD1 might exist 
in multiple active oligomeric states presents a challenging system for designing kinetic 
experiments that reveal useful insights into function and mechanism.  Since activation by 
dGTP  is  complicated  by  the  fact  that  it  is  also  a  substrate,  we  began  by  investigating 
activation by GTP, which does not compete for substrate binding to the catalytic site.  
 The  activation  of  dUTP  hydrolysis  by  GTP  was  studied  using 3H-labeled  dUTP 
(Fig.  1A,  B).    dUTP  was  selected  for  these  studies  because  it  is  present  at  high 
concentrations in resting immune cells that express SAMHD1 and it reacts similarly as 
all other dNTPs (Fig. S1).  Variable concentrations of dUTP in the presence of five fixed 
GTP concentrations (0.01 – 5 mM) were incubated with SAMHD1 (0.5 µM monomer).  
The concentration dependence of the velocities showed no evidence of sigmoidicity and 
accordingly, the data were globally fit to eq 1 (Fig. 1C).  The K m
app, dUTP values decreased 
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as the GTP activator was increased giving a limiting K m
dUTP = 1.5 ± 0.1 mM at saturating 
GTP activator, with K act
GTP = 163 ± 30 µM, and V max
dUTP/[monomers] = kcat
dUTP = 5 ± 0.2 
s-1.    Normalization  of  Vmax
dUTP  to  monomer  concentration  is  justified  because  plots  of 
velocity against SAMHD1 monomer concentration were linear in the 
range 0.2 to 10 uM when the GTP activator concentration was  ≥ 50 µM. (Fig. S2).   
A secondary plot of K m
app against 1/[GTP] activator concentration clearly shows that 
the catalytic site has undetectable affinity for dUTP in the absence of GTP (Fig. 1D), and 
that GTP acts to lower the Km
app, dUTP, without changing Vmax
app, dUTP (Fig. S3A). 
Therefore, GTP is a Km-type essential activator (A), and high dUTP substrate 
concentrations (S) always pull the equilibrium towards the active EAS complex even at 
low activator concentrations.  The cellular implication of this mechanism is that as long 
as the activator concentration exceeds that of the enzyme, dNTP binding can in principle 
pull the system all the way to the activated EAS state.  
To confirm the ordered essential activation mechanism we also performed a kinetic 
analysis  where  dUTP  hydrolysis  was  measured  at  fixed dUTP  concentrations  (0.2  to  5 
mM) and the GTP activator concentration was varied in the range 0.01 to 5 mM (Fig. 
1E).  As expected, the secondary replot of 1/K act
app, GTP against [dUTP] was linear, with 
the  y-intercept  providing  the  true  Kact
GTP  =  133  ±  10  µM  (Fig.  1F).    The  important 
implication from this result is that GTP binds to activator site(s) of SAMHD1 monomers 
or dimers in the absence of substrate.  The secondary plot 1/V max
app, dUTP against 1/[dUTP] 
also showed the expected linear response from an ordered-essential activation mechanism 
(Fig. S3B), and order-of-addition experiments demonstrated that these kinetic properties 
of SAMHD1 are invariant (Fig. S4).  We note that oligomerization is enzyme 
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concentration  dependent,  and  therefore,  the  Kact  parameters  for  activators  of  SAMHD1 
are  apparent  values  that  hold  for  the  dilute  concentrations  of  monomer  used  in  these 
experiments.   
To summarize, SAMHD1 shows classical ordered binding of activator and substrate.  
Despite the complex nature of SAMHD1 activation these data indicate that binding of the 
dUTP  substrate  to  the  four  catalytic  sites,  as  well  as  GTP  activator  binding  to  the 
guanine-specific A1 activator sites, occur independently without any detectable 
cooperativity.  Accordingly, in terms of kinetic models it is sufficient to consider only a 
phenomenological EAS complex.  We defer to the discussion the likely mechanistic basis 
for  the  apparent  absence  of  cooperativity  in  this  reaction.    In  addition,  these  data  in 
isolation do not provide information as to whether the A2 activator site is occupied by 
GTP, or alternatively, dUTP. 
Activation and Inhibition by dGTP and dGTPαS.  Unlike GTP, dGTP can activate its 
own hydrolysis and is known to serve as a trans-activator for hydrolysis of other substrate 
dNTPs at low concentrations (17).  However, it should also act as an inhibitor of dNTP 
hydrolysis  at  higher  concentrations  (20,  22).    To  explore  these  properties  of  dGTP  we 
determined  the  concentration  dependence  of  the  initial  rates  of  dGTP  hydrolysis  at  a 
SAMHD1 concentration of 0.2 µM and variable concentrations of dGTP in the range 5 
µM to 5 mM (Fig. 2A, closed circles).  Although a self-activating substrate is expected to 
show a sigmoidal concentration dependence to the initial velocities (23), these data did 
not require the use of the Hill equation (K 0.5
dGTP = 1.9 ± 0.3 mM, and k cat
dGTP = 2 ± 0.2 s -
1).    We  discuss  later  how  the  unusual  activation  mechanism  of  SAMHD1  can  mask 
expected cooperativity (see Discussion).  
42
We found that GTP was unable to stimulate the hydrolysis of dGTP beyond the self-
activation provided by dGTP alone.  Addition of a saturating 5 mM fixed concentration 
of  GTP  to  reactions  where  dGTP  was  the  variable  substrate  resulted  in  a  simple 
hyperbolic velocity profile that was indistinguishable from dGTP alone (Fig. 2A, open 
circles).  The steady-state kinetic parameters for dGTP hydrolysis derived from this data 
are very similar to those observed above in the GTP activation of the dUTP reaction and 
the dGTP self-activation data (K0.5
dGTP = 2.1 ± 0.4 mM, kcat
dGTP = 2 ± 0.5 s-1).  
Additionally,  we  discovered  that  the  steady-state  turnover  of  SAMHD1  with  a  low 
concentration  of  dGTP  (25 µM)  could  not  be  stimulated  by  spiking  with  5  mM  GTP 
activator  (Fig.  2B).    This  intriguing  finding  suggested  that  GTP  cannot  access  its  A1 
activator site during steady-state turnover of the activated enzyme form.  The basis for 
this intriguing property is explored in the experiments below. 
We  further  explored  whether  dGTP  could  activate  the  hydrolysis  of  dUTP  at  low 
concentrations,  and  then  inhibit  the  reaction  of  dUTP  by  competitive  binding  to  the 
catalytic site as the concentration of dGTP was increased.  These outcomes were born out 
in  steady-state  rate  measurements  (Fig.  2C),  where  the  dUTP  concentration  was  held 
constant at 1 mM and dGTP was varied in the concentration range 5 µM to 5 mM. These 
data were simulated by fixing the K m
dUTP at the value obtained with the activator GTP, 
while allowing K act
dGTP, K i
dGTP and k cat
dUTP to float (see eqs 5-8).  If K m
dUTP was allowed 
to  float,  similar  results  were  obtained  but  the  fitting  errors  increased.  The  constants 
obtained for dGTP were K act
dGTP = 65 ± 33 µM, K i
dGTP = 146 ± 74 µM, and k cat
dUTP = 5.5 
± 1.5 s-1. Thus, GTP and dGTP have similar activation constants for dUTP hydrolysis but 





The crystal structure of SAMHD1 bound to dGTPαS shows that the R stereoisomer of 
this analogue occupies all activator sites and catalytic sites of the tetramer suggesting that 
it should serve as a stable dGTP analogue for mechanistic studies (20).  We found that 
racemic  dGTPαS  was  a  very  slow  substrate  in  the  absence  and  presence  of  trans-
activation by GTP (t 1/2 = 24 hrs) (Fig. S5), which is consistent with the crystal structure 
showing that dGTPαS can bind to the A1 and A2 activator sites as well as the catalytic 
sites (20). Supporting the suggestion that dGTPαS can self-activate, it also served as a 
weak trans-activator for dUTP hydrolysis at low concentration (K act
dGTPαS = 8 ± 2 µM, 
kcat
dUTP = 0.9 ± 0.1 s -1) and an inhibitor at higher concentrations (K i
dGTPαS = 67 ± 19 µM) 
(Fig. 2C).  These properties of dGTPαS, which may underestimate its potency by a factor 
of two due to the use of a racemic mixture, makes it useful for comparing the discrete 
effect of a non-substrate activator (GTP) with that of activators that are known to bind to 
all activator and substrate sites of SAMHD1 (dGTP, dGTPαS) (22, 20). 
Long-lived Activated States of SAMHD1.  The observation that a high concentration of 
GTP was not able to further stimulate SAMHD1 dGTPase activity at low dGTP 
concentrations (Fig. 2B), required us to consider that the activated form of the enzyme 
was not in equilibrium with free activator during turnover.  To test this we performed a 
series  of  dilution-jump  experiments  where  a  high  concentration  of  SAMHD1  (10  µM) 
was pre-incubated with high concentrations of GTP activator and/or dUTP substrate and 
then rapidly diluted 100-fold into a solution that contained millimolar concentrations of 
the  dUTP  substrate  but  no  activator  (Fig.  3A).  This  experiment  probes  the  kinetic 
stability of activated enzyme form(s) that are generated in the pre-jump conditions.   
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When GTP and dUTP were present in the pre-jump solution, a rapid initial burst rate 
of dUTP hydrolysis was observed in the post-jump reaction (v i = 0.28 ± 0.02 µM/s) that 
was 6-fold greater than a standard steady-state reaction of fully activated SAMHD1 under 
equivalent conditions (5 mM GTP, 1 mM dUTP, 100 nM SAMHD1 monomer) (Fig. 3A).  
This burst phase corresponds to over 2500 turnovers of enzyme active sites.  We attribute 
the  post-jump  burst-decay  rate  constant  to  the  slow  disappearance  of  the  highly  active 
form of SAMHD1 generated in the pre-jump solution (k inact = 0.0011 ± 0.0001 s
-1; t1/2 = 
10 ± 1 min).  At the conclusion of the burst-decay period, a second lower activity form 
persisted and produced a linear rate of dUTP hydrolysis for at least 6 hours (v ss = 0.02 ± 
0.002 µM/s).  This rate is comparable to the calculated steady-state rate of fully-activated 
SAMHD1 under these conditions ([GTP] = 5 mM, [dUTP] = 1 mM and [E] = 100 nM 
monomer), indicating that this long-lived form is the steady-state active form of 
SAMHD1.  Thus,  using  pre-jump  conditions  containing  both  dUTP  substrate  and  GTP 
activator,  two  distinct  forms  of  SAMHD1  can  be  detected  in  the  post-jump  reaction.  
These forms differ with respect to their half-lives for decay (~ 10 min and greater than 6 
hours), as well as their catalytic activities. 
The  post-jump  results  were  very  dependent  on  the  composition  of  the  pre-jump 
solution.    When  GTP  alone  was  present  in  the  pre-jump,  the  same  two  kinetic  phases 
were  observed  as  with  the  combination  [GTP  +  dUTP].    However,  when  the  pre-jump 
contained  only  SAMHD1,  or  enzyme  and  dUTP  alone,  the  burst  was  abolished  and 
exceedingly slow linear rates were observed in the post–jump reaction with dUTP (Fig. 
3A,  closed  and  open  squares).    With  only  GTP  in  the  pre-jump,  the  post-jump  burst 
amplitude  was  reduced  by  50%,  but  the  burst-decay  rate  constant  and  steady-state  rate 
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(normalized for active enzyme) were essentially unchanged (k inact = 0.0010 ± 0.0003 s
-1, 
vss  =  0.02  ±  0.001  µM/s).  Consistent  with  the  surprising  finding  that  GTP  could  not 
stimulate steady-state turnover using low concentrations of dGTP (see Fig. 2B), addition 
of  GTP  to  the  post-jump  solution  containing  1  mM  dUTP  did  not  enhance  the  burst 
properties  or  steady-state  linear  rate  obtained  from  a  pre-jump  solution  that  contained 
both GTP and dUTP (Fig. 3B).  This finding establishes that the GTP activated form of 
SAMHD1  behaves  like  the  dGTP  activated  enzyme  and  is  not  in  communication  with 
free activators during steady-state turnover. 
When  the  substrate/self-activator  dGTP  was  present  in  the  pre-jump,  the  post-jump 
behavior was identical to the combination [dUTP + GTP] (Fig. 3C).  We could establish a 
requirement for dGTP binding to the A2 or catalytic sites by inserting a pre-jump delay 
before dilution, thereby consuming any free dGTP that was not protected by being bound 
to  the  enzyme.    As  the  pre-jump  delay  was  increased,  the  post-jump  burst  amplitude 
decreased until it reached a plateau level of 50% of maximal.  This is identical to that 
observed above when only GTP activator was present in the pre-jump (Fig. 3A).  These 
results  are  consistent  with  a  model  where  GTP  and  dGTP  behave  identically  when 
interacting with the guanine specific A1 site, but binding of dGTP or dUTP to the A2 and 
catalytic sites is required to achieve full-activation.  
We conclude from the above dilution-jump results that activator and substrate must 
be present in the pre-jump solution to fully generate the two active enzyme species that 
are detected in the post-jump phase. Maximal activation is provided by (i) the 
combination GTP (A1 site only) and dUTP (A2 and catalytic sites), or (ii) dGTP alone 
(all sites).  Lesser activation is observed with GTP alone, which can only occupy the A1 
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site.  Further  evidence  for  this  interpretation  is  found  below  and  in  the  Discussion. 
Importantly,  once  activation  occurs  SAMHD1  is  no  longer  in  equilibrium  with  free 
activator while it performs steady-state turnover. We report further salient kinetic 
properties of the dilution-jump reactions in Fig. S6A-D.  
(d)NTP Induced Changes in Oligomeric State of SAMHD1.  We hypothesized that the 
slowly  decaying  active  species  present  in  the  dilution-jump  experiments  might  reflect 
dissociation of the active tetramer, or alternatively, dissociation of one or more activating 
nucleotides.  To elucidate the oligomeric species that were present during the different 
phases  of  the  post-jump  period  we  performed  an  analogous  procedure  except  that  the 
samples  taken  from  the  post-jump  reactions  at  various  times  were  mixed  with  50  mM 
glutaraldehyde  (Fig.  4).    The  standard  dilution-jump  cross-linking  experiment  involves 
pre-incubation  of  SAMHD1  (10  µM)  with  various  combinations  of  GTP  activator  (0.5 
mM),  dUTP  (1  mM),  dGTP  (1  mM),  dGTPαS  (5  mM),  for  10  s  before  rapid  100-fold 
dilution into a post-jump solution containing 1 mM dUTP substrate.   
Samples subjected to this procedure and cross-linked immediately after dilution are 
shown in Figure 4A after separation of monomer, dimer and tetramer using denaturing 
polyacrylamide  gel  electrophoresis  and  visualization  with  silver  staining.    The  salient 
findings from these data are (i) SAMHD1 in the absence of guanine nucleotides exists as 
an inactive monomer-dimer equilibrium even in the presence of 1 mM dUTP in the post-
jump, (ii) highly efficient tetramer formation requires either dGTP alone, [GTP + dUTP], 
or dGTPαS in the pre-jump solution, and (iii) GTP alone in the pre-jump induces about 
25% the amount of tetramer as the combined presence of [GTP + dUTP] as long as dUTP 
is  present  in  the  post-jump.    These  effects  of  nucleotides  on  the  formation  of  tetramer 
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exactly parallel their effects on activity in the initial times of the post-jump kinetic assay. 
We  performed  a  series  of  cross-linking  studies  as  a  function  of  post-jump  time  to 
show that the kinetic phases in the kinetic dilution-jump experiments were not correlated 
with  dissociation  of  the  tetrameric  state  of  SAMHD1.    The  relative  amounts  of  each 
oligomeric species at each post-jump time were quantified by imaging the silver stained 
gels as summarized in Fig. 4B.  In all conditions where tetramer was formed in the pre-
jump step (dGTP, GTP, dGTPαS, [GTP + dUTP]), it was found to persist intact during 
the  entire  post-jump  burst-decay  time  (60  min).    Thus,  the  initial  burst-decay  period 
cannot be attributed to dissociation of the tetramer.  Moreover, tetramer was still present 
in significant amounts six hours after the dilution jump when dUTP + GTP or dGTP were 
present  in  the  pre-jump  (Fig.  4B).    Thus,  the  observed  changes  in  activity  must  result 
from other more subtle alterations in the enzyme structure that are not detected by the 
cross-linking method. 
We were curious if the highly active form of SAMHD1 present in the activator-free 
post jump solution retained tightly bound activator nucleotides.  To address this question 
we performed reactions similar to the pre-jump kinetics where SAMHD1 was mixed with 
[γ-32P] GTP and [5-3H] dUTP and then subjected to a spin column gel filtration 
chromatography  step  to  separate  free  and  bound  (d)NTPs  (Fig.  S7A).    To  evaluate  the 
time course for release of the bound nucleotides that were retained after the first column 
step, a second spin column step was performed on the flow-through fraction from the first 
column.    The  simultaneous  use  of  [ γ-32P]  GTP  and  [5- 3H]  dUTP  and  dual-channel 
scintillation  counting  allowed  the  precise  ration  of  both  nucletides  to  be  determined.  
Further, determination of the amount of tetramer present after each column step allowed 
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for estimation of the stoichiometry of GTP and dUTP binding to each monomer subunit 
of the tetramer (see Methods and Fig. S7B).  After the first column, an average of 1.3 
and 0.87 equivalents of [5- 3H] dUTP and [ γ-32P] GTP were bound per monomer of the 
tetramer form, consistent with the A1 and A2 sites being occupied by GTP and dUTP, 
respectively.    Since  the  catalytic  site  has  a  high  Km  we  assume  that  dUTP  is  rapidly 
released from this site during the spin column step leaving only the A2 site occupied. The 
time course for release of the bound GTP and dUTP was largely complete in the one-
minute  delay  time  before  running  the  second  spin  column,  from  which  we  estimate  a 
half-life for activator release of about one minute (Fig. S7B).  We conclude that GTP and 
dUTP  activators  are  bound  in  one-to-one  stoichiometry  with  each  monomer  subunit  of 
the tetramer, and that their release greatly precedes that of tetramer dissociation. 
We used the velocity sedimentation method to complete the characterization of the 
linkage  between  the  oligomeric  equilibria  of  SAMHD1  and  binding  of  the  nucleotides 
GTP  and  dGTPαS.    The  raw  scan  data  were  converted  to  a  c(S)  distribution  and  then 
fitted  to  a  monomer-dimer-tetramer  model  as  described  in  Methods.    SAMHD1  in  the 
concentration  range  2  to  8  µM  total  monomer  largely  existed  in  a  monomer-dimer 
equilibrium  in  the  absence  of  nucleotides  (Fig.  5A  (red)  and  Fig.  S8).    The  monomer 
form dominated at the lower concentrations, but at 8 µM total monomer the monomer-
dimer equilibrium slightly favored dimer (K D = 2.3 µM; 95% CI: 2.2 to 2.4).  Even at the 
highest monomer concentration tested, less than 4% of total monomer was in the tetramer 
form  in  the  absence  of  nucleotide  (KT  ≥  30  µM).    Addition  of  1  mM  GTP  pushed  the 
monomer-dimer  equilibrium  significantly  towards  dimer  (KD
GTP  =  0.38  µM;  95%  CI: 
0.33 to 0.42), but induced a much smaller increase in tetramer (K T
GTP = 16 µM; 95% CI: 
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15 to 17) (Fig. 5A).  In contrast, the predominant effect of 1 mM dGTPαS was to shift the 
dimer-tetramer equilibrium to favor tetramer (K T
dGTPαS = 0.41 µM; 95% CI: 0.38 to 0.43, 
KD
dGTPαS = 0.89 µM; 95% CI: 0.77 to 1.0) (Fig. 5C).  These effects of GTP and dGTPαS 
on  the  oligomeric  equilibria  recapitulate  their  effects  on  the  dilution-jump  kinetics  and 
cross-linking and support the model where GTP induces dimerization, but occupation of 
the A2 and substrate sites is required for tetramerization. 
 
◦ Discussion 
Nucleotide-Dependent Ordered Assembly of SAMHD1. These diverse measurements 
allow  for  the  construction  of  a  minimal  model  for  nucleotide  dependent  activation  of 
SAMHD1 (Fig. 6).  In the absence of nucleotides, SAMHD1 is trapped in an equilibrium 
between monomer (M) and dimer (D) forms and is unable to generate active tetramer (T) 
(Fig. 6A).  Binding of GTP to the A1 site (but not the A2 or the catalytic sites, see below) 
strongly  shifts  the  equilibrium  towards  dimer,  with  little  effect  on  the  tetramerization 
equilibrium  (Fig.  6A).    The  structural  basis  for  the  increased  dimer  affinity  apparently 
results from docking of the guanine base of GTP into the highly specific guanine binding 
site on one monomer and the formation of electrostatic interactions between its 
triphosphate  group  and  the  second  monomer  of  the  dimer  (Fig.  S9A,  B)  (22).    Hence, 
GTP serves as a nucleotide tether to bring together monomers.  Since GTP concentrations 
exceed that of dGTP by about 1000-fold in the cell (3), and there is no large difference in 
the  activation  constants  for  these  nucleotides,  the  implication  of  these  findings  is  that 
GTP  occupies  the  guanine-specific  A1  site  under  physiological  conditions,  not dGTP.  
An additional advantage of using GTP as the primary activator is that GTP levels are not 
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depleted by SAMHD1, allowing the activated tetramer to persist (see below).  
Based on the limited ability of GTP alone to induce tetramerization and the results 
from  structural  modeling  (Fig.  S9C),  we  propose  that  the  2́-hydroxyl  group  of  GTP 
sterically  prevents  binding  of  GTP  to  both  the  A1  and  A2  activator  sites.    Thus,  as 
suggested  above,  GTP  is  restricted  to  the  A1  activator  site,  and  the  A2  site  must  be 
occupied by a dNTP co-activator to efficiently produce tetramer (i.e. dUTP in the studies 
here).  The contention that any dNTP can bind to the A2 site is supported by a crystal 
structure of SAMHD1 with dGTP bound to the specific A1 site and dATP bound to the 
A2 site (22), structural modeling showing that the A2 site nicely accommodates dUTP 
(Fig.  S9D,  E),  the  binding  of  one  equivalent  of  dUTP  to  each  monomer  only  in  the 
presence  of  GTP  (Fig.  S7B),  and  the  dilution-jump  cross-linking  showing  that  when 
dUTP  is  added  in  addition  to  the  A1  site  activator  GTP,  tetramer  is  efficiently  formed 
(Fig. 4).   
To understand the combined effect of activator and substrate on oligomerization we 
used  the  relatively  inert  dGTPαS  analogue  (20).    Binding  of  dGTPαS  shifted  the 
equilibrium  dramatically  towards  tetramer  as  compared  to  GTP  alone,  an  effect  that 
resulted  from  the  same  increase  in  dimer  affinity  observed  with  GTP,  and  a  further 
enhancement of the tetramerization constant (Fig. 5, 6).  This result is consistent with the 
crystal  structure  showing  that  dGTPαS  can  occupy  the  A1,  A2  and  catalytic  sites,  and 
that  binding  of  dGTPαS  to  the  A2  site  forms  bridging  interactions  within  the  tetramer 
(dimer-dimer) interface involving its base and triphosphate groups (Fig. S10A) (20).  
Ordered  Pathway  for  Activation.    The  combined  activation  and  oligomerization  data 
using  GTP  alone,  [GTP  +  dUTP],  dGTP  and  dGTPαS  define  an  ordered  pathway  for 
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nucleotide activation of SAMHD1.  The first event is occupation of the A1 site by GTP, 
which  promotes  dimerization,  followed  by  occupancy  of  the  A2  site  by  a  co-activator 
dNTP,  which  is  thermodynamically  coupled  with  binding  of  substrate  dNTP  to  the 
catalytic site.  The combined effect of dNTP binding to the A2 and catalytic sites pulls 
the entire set of equilibria towards active tetramer.  This is the structural and temporal 
basis  for  the  ordered-essential  activation  mechanism.    The  dilution  jump  and  direct 
binding  measurements  of  GTP  and  dUTP  indicate  that  once  activating  nucleotides  are 
bound  they  are  not  required  to  maintain  tetramer  stability.    This  result  leads  to  the 
unanticipated conclusion that activating nucleotides serve much like chaperones in 
promoting tetramer formation, but once tetramer is formed it persists without the 
requirement for bound activator nucleotides.  
Quite surprisingly, none of the experimental data for activation and catalysis revealed 
any evidence for cooperativity.  This non-intuitive and perplexing finding was brought 
into  focus  using  kinetic  simulations  that  included  the  step  of  forming  a  long-lived 
activated  state  such  as  that  depicted  in  Fig.  6B.    These  simulations  revealed  that 
cooperativity  would  only  be  apparent  in  the  pre-steady  state  regime when such a 
mechanism  operates.    Since  initial  velocities  are  assumed  to  be  instantaneous,  the 
hysteresis  in  the  system  would  not  be  observed  and  simple  steady-state  initial  velocity 
equations would still hold.    
Long-lived SAMHD1.  An ordered-essential activation mechanism involving GTP 
activation  and  a  long-lived  tetramer  has  several  important  implications  for  the  cellular 
activity of SAMHD1. Since all dNTPs are substrates for SAMHD1, the driving force for 
formation of the active Michaelis complex would be provided by the concentration of the 
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entire dNTP pool.  The observation that an active tetrameric form of SAMHD1 is stable 
for  over  six  hours  in  the  absence  of  activating  nucleotides  is  relevant  to  the  condition 
where dNTP pools have been largely depleted by SAMHD1.  If SAMHD1 immediately 
dissociated  to  inactive  dimer  and  monomer  states  under  low  dNTP  conditions,  and  if 
dGTP  were  the  sole  A1  site  activator,  the  pool  levels  would  not  readily  reach  the 
nanomolar regime observed in resting macrophages or CD4+ T cells.  Such low dNTP 
pool levels have been implicated in the HIV-1 restriction activity of SAMHD1 in these 
cell types because reverse transcriptase is much less efficient when dNTP substrates are 
scarce (24, 25).   
An enigmatic feature of SAMHD1 activity in resting immune cells is the presence of 
elevated dUTP levels in an otherwise depleted dNTP pool background (26, 27).  Given 
our  findings  that  dUTP  is  an  excellent  substrate,  there  must  be  as  of  yet  undiscovered 
regulatory  mechanisms  that  allow  dUTP  levels  to  persist  or  accumulate  after  the  other 
dNTPs  have  been  depleted.    Since  dUTP  incorporation  into  HIV-1  cDNA  has  been 
implicated as a related antiviral defense mechanism (28, 29), a further understanding of 
the mechanisms that regulate nucleotide pools during the transition from active to resting 








Figure 2.1 Activation of dUTP hydrolysis by GTP. Activation of dUTP hydrolysis by 
GTP.  SAMHD1 (0.5 µM) was incubated with increasing concentrations of 3H-dUTP in 
the presence of five GTP activator concentrations (0.01–5 mM).  (A) Time courses for 
dUTP hydrolysis using the C18-RP TLC plate assay. (B) Linear initial rates for formation 
of the 3H-dU product. (C) Initial velocities were found to follow a hyperbolic dependence 
on dUTP concentration with no evidence of sigmoidicity.  Curves are from global non-
linear least squares best fit to all of the data using eq 1.  (D) Secondary plot of K m
app, dUTP 
against  1/[GTP].  (E)  GTP  concentration  dependence  of  the  dUTP  hydrolysis  rates  at 
increasing [dUTP]. (F) Secondary plot of 1/Kact


















Figure 2.2 Self-activation, transactivation, and inhibition by dGTP. (A) dGTP self-
activation of dGTP hydrolysis and trans-activation of dGTP hydrolysis by 5 mM GTP.  
The data sets were normalized to total active sites and are indistinguishable.  (B) Addition 
of  5  mM  GTP  during  steady-state  hydrolysis  of  25  µM  dGTP  by  0.5  µM  SAMHD1 
provides no additional activation. (C) Activation and inhibition of dUTP hydrolysis by 
dGTP  and  dGTPαS.    Curves  were  generated  using  the  simulation  program  Dynafit  to 
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Figure 2.3 Dilution-jump kinetic experiments for dUTP hydrolysis. High 
concentrations  of  SAMHD1  and  various  nucleotide  combinations  were  incubated  as 
indicated  in  pre-  and  post-jump  reactions.  (A)  SAMHD1  was  incubated  with  GTP  (0.5 
mM) and dUTP (5 mM), GTP alone (0.5 mM), dUTP alone (5 mM), or no nucleotide 
prior to dilution. (B) Inclusion of 0.5 mM GTP in the post-jump reaction did not enhance 
the post-jump kinetics. For comparison, the dashed line shows the curve from the dUTP-
only  post-jump  condition  in  panel  (A).    (C)  Time  dependence  of  pre-jump  reactions 
containing only dGTP (5 mM).   








































































Figure  2.5  Sedimentation  velocity  experiments  to  evaluate  the  effects  of  GTP  and 
dGTPαS on the oligomeric state of SAMHD1. (A) SAMHD1 alone (8 µM) and in the 
presence  of  1  mM  GTP  or  (B)  SAMHD1  alone  (8  µM)  and  in  the  presence  of  1  mM 
dGTPαS were dialyzed and analyzed by sedimentation velocity centrifugation. Raw scan 








































of long-lived activation. All values given are in concentration units of micromolar.  (A) 
Summary of the effects of GTP and dGTPαS on the oligomeric equilibria. The values for 
KD  and  KT  are  for  the  indicated  concentration  of  nucleotide.  (B)  Model  for  ordered-
essential activation and oligomerization by GTP activators and dNTP co-
activator/substrates  involving  the  formation  of  a  long-lived  activated  tetramer.      The 
E(A1A2)4S4 complex is depicted as isomerizing (K iso) to a long-lived tetramer (brackets) 
that  performs  steady-state  turnover.    This  form  only  slowly  reconverts  to  the  loosely 
associated tetramer form that is in equilibrium with monomer, dimer and free nucleotides.  
The  model  also  indicates  that  the  activator  sites  of  the  long-lived  tetramer  do  not 
communicate with free (d)GTPs during steady-state turnover of substrate dNTPs.  
Although  not  depicted,  the  actively  cycling  tetramer  does  not  require  the  presence  of 





protein  1  (SAMHD1).  Two  microliter  samples  were  removed  at  indicated  times  and 
quenched  by  spotting  onto  a  FITC  (UV254)  impregnated  C18-reversed  phase  thin  layer 
chromatography (TLC) plate.  TLC plates were developed in 50 mM KH 2PO4 (pH 4.0) to 
separate substrate from products.  Plates were visualized using a Gel Doc (Bio-Rad) UV 
































Figure  2.8  Steady-state  measurements  of  the  rate  of  dUTP  (1  mM)  hydrolysis  at 
various SAMHD1 concentrations. (A) dUTP hydrolysis rate as a function of SAMHD1 
monomer concentration at various concentrations of GTP activator.  There is no evidence 
for significant nonlinear behavior in the range 50 µM to 5 mM [GTP].  (B) At very low 
concentrations  of  GTP  (20 µM)  and  SAMHD1  the  dUTP  hydrolysis  shows  parabolic 
upward curvature indicative of changes in the active oligomeric state at this low 
concentration of activator. Such changes are expected based on the enzyme concentration 





















































































Figure 2.9 Secondary replots to confirm the ordered essential activation mechanism. 
(A)  The  secondary  plot  of  Vmax
app,  dUTP   against  [GTP]  activator  concentration  clearly 
demonstrates  that  dUTP  substrate  binding  can  always  pull  the  equilibrium  towards  the 
active EAS complex at any concentration of activator. (B) Secondary plot 1/V max
app, dUTP 


















































































Figure 2.10 The sequence of reagent addition shows no effect on the kinetic 
properties of SAMHD1. Order-of-addition reactions contained GTP (A, 0.5 mM) trans-
activator and either [5- 3H] dUTP (1 mM) or [8- 3H] dGTP (1 mM) substrate. Reactions 
were  initiated  by  addition  of  SAMHD1  (0.5 µM)  to  samples  containing  GTP  and  [3H] 
dNTP  substrate  (0  min).  Alternatively,  SAMHD1  was  pre-incubated  with  GTP  for  the 
indicated  time  (1,  30  or  60  min)  and  then  initiated  by  addition  of  substrate.  Substrate 























































E S E S
63
(dGTPαS; 1 mM) with SAMHD1 (0.5 µM) in the presence or absence of GTP (50 µM). 
Reaction progress was monitored at 0, 1, 3 and 24 hr by spotting two microliter samples 
on C18-RP TLC (UV 254) plates.  Results show that dGTPαS is a very slow substrate both 


































Figure 2.12 Kinetic characteristics of various dilution-jump reactions. (A) The burst 
amplitude was found to be independent of GTP concentration in a pre-jump solution that 
contained 50 to 500 µM GTP and 1 mM dUTP, indicating that the active enzyme form 
present in the post-jump burst-decay phase is completely assembled in the pre-jump time 
period over a wide range of GTP concentrations (≤10 s).  (B) The decay rate (k inact) in 
post-jump reaction was independent of the SAMHD1 concentration in the pre-jump, but 
the burst amplitude and the rate of the second kinetic phase were directly proportional to 
the  SAMHD1  concentration  in  the  pre-jump.  These  findings  established  that  the  burst-
decay phase is a uni-molecular decay process and that the second phase follows simple 
steady-state  kinetic  behavior.    (C)  The  steady-state  rate  of  the  post-jump  linear  phase 
increased  with  the  dUTP  concentration  present  in  the  post-jump  solution.  (D)  Delay-
before-dilution experiments using GTP and dUTP in the pre-jump solutions established 
that as the substrate is depleted during the delay time before dilution, the burst amplitude 
in  the  post-jump  reaction  is  reduced.    Eventually,  as  the  delay  is  increased  to  a  length 
where all of the pre-jump substrate is consumed, the burst amplitude reaches the ~50% 
level observed when only GTP activator is present in the pre-jump solution.  The similar 
results  achieved  with  GTP  alone  in  the  pre-jump  and  using  long  pre-jump  delay  times 
with  activator  and  substrate  exclude  the  possibility  that  the  long-lived  active  forms  of 






























































































and release kinetics. (A) Schematic of the experimental design showing the spin column 
steps  to  remove  unbound  nucleotides.  GTP*  and  dUTP*  represent  the  32P-  and  3  H-
labeled nucleotides, respectively. In some experiments, the collection tube after the first 
spin column contained 1 mM unlabeled dUTP to mimic the postjump conditions of the 
dilution-jump  protocol.  (B)  Denaturing  PAGE  was  used  to  separate  and  quantify  the 
cross-linked oligomers of SAMHD1 at the indicated step. The moles of GTP and dUTP 
present  in  the  column  excluded  volume  after  each  spin  step  were  calculated  from  the 
known nucleotide-specific activity by scintillation counting. Because activator 
nucleotides are only expected to be tightly bound to the tetramer form, the stoichiometry 
is expressed as the ratio of nucleotide bound to each monomer of tetrameric SAMHD1 
[(monomer)tet]. The amount of monomer was determined by quantifying the images of 
the  gels,  where  the  amount  of  monomer  in  the  tetrameric  form  =  (moles  monomer 
loaded)  ×  I  tet/(I  tet  +  I  dim  +  I  mon),  and  I  tet,  I  dim,  and  I  mon  are  the  integrated 
intensities of the tetramer (T), dimer (D), and monomer (M) bands. The greater amounts 
of dUTP and GTP that are retained after the second spin when dUTP was present in the 
collection tube after the first spin show that cold dUTP is not accessible to the site where 
dUTP* is bound. This result is consistent with dUTP being bound to the sequestered A2 
site. Because the second column was run 2 min after the first column, the half-life for 













Figure  2.14  Concentration  dependence  of  SAMHD1  sedimentation  velocity  data. 
The raw scan data were fitted to a c(S) distribution as described in the methods. (A) The 
indicated concentration of SAMHD1 was dialyzed and analyzed by sedimentation 
velocity. (B) The indicated concentration of SAMHD1 was dialyzed in the presence of 


























































dGTPαS  in  the  A1  site  is  stabilized  primarily  by  the  monomer-monomer  interface 
between chains A and B. dGTP αS in the Activator 2 site makes extensive contact at the 
dimer-dimer  interface.  Occupation  of  both  A1  and  A2  sites  is  facilitated  by  contacts 
between  the  ligands  and  the  tetrameric  form  of  SAMHD1.  (B)  Tetrameric  SAMHD1 
produces  a  compact,  catalytic  site  capable  of  accommodating  all  dNTPs,  including 
dGTPαS  (pink).  Essential  contact  and  catalytic  residues  are  highlighted  and  Mn2+  is 
shown  as  a  purple  sphere.  Residues  are  color-coded  by  chain  based  on  Figure  S13A. 
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Chapter 3: Diverse fates of uracilated HIV-1 DNA during infection of myeloid 
lineage cells 
 
Abstract:  We  report  that  a  major  subpopulation  of  monocyte-derived  macrophages 
(MDMs)  has  a  metabolic  phenotype  leading  to  high  levels  of  dUTP  incorporation  into 
HIV-1 DNA during reverse transcription (U/A pairs). Uracilated viral DNA products are 
degraded by the nuclear uracil base excision repair (UBER) machinery with less than 1% 
of  the  uracilated  DNA  successfully  integrating.  Although  uracilated  proviruses  showed 
relatively few mutations, the viral genomic RNA was highly mutated, suggesting error-
prone  transcription  and/or  repair.  Despite  the  restrictive  MDM  environment,  infectious 
virus was still produced. Viral DNA isolated from blood monocytes and alveolar 
macrophages  (but  not  T  cells)  of  drug-suppressed  HIV-infected  donors  also  contained 
detectable  uracils.  The  presence  of  viral  uracils  in  short-lived  circulating  monocytes 
suggests  their  recent  infection  through  contact  with  virus  producing  cells  in  a  tissue 
reservoir.  These  findings  characterize  a  new  viral  defense  mechanism  involving  host 
UBER that is relevant to the establishment and persistence of HIV-1 infection. 
Introduction 
The uracil nucleobase plays a central role in adaptive and innate immunity against HIV-1 
when it is found in DNA rather than RNA 1,2.  The most well characterized uracil-centric 
innate immune response involves host cell DNA cytidine deaminase enzymes 
(APOBECs),  which  selectively  deaminate  cytosine  residues  during  (-)  strand  DNA 
synthesis thereby rendering the viral genome nonfunctional by hypermutation 
(C/Gà T/A). Work from our lab has suggested the presence of another uracil-mediated 
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HIV-1  restriction  pathway  involving  the  incorporation  of  dUTP  into  viral  DNA  by 
reverse  transcriptase  to  produce  U/A  base  pairs  (“uracilation”)3.  The  dUTP-dependent 
pathway is thought to be restricted to non-dividing immune cells such as macrophages, 
monocytes and resting CD4+ T cells because only non-dividing cells have the requisite 
low levels of canonical dNTPs and elevated ratios of dUTP/TTP 4,5. Notably, U/A pairs 
resulting from dUTP incorporation are “invisible” to normal DNA sequencing methods 
and they retain the coding potential of normal T/A base pairs.  Despite the similarity of 
U/A and T/A pairs, the presence of uracil in DNA has the potential to introduce diverse 
effects on viral infection including transcriptional silencing and engagement of the host 
uracil base excision repair (UBER) pathway 6-8. The presence, persistence, and ultimate 
fate of U/A pairs in HIV-1 proviral DNA is unexplored and is important for 
understanding the potential of tissue macrophages to establish and maintain a long-term 
HIV reservoir.
Results 
Uracilation of HIV DNA results from the unique nucleotide metabolism in myeloid 
phagocytic cells. We hypothesized that viral uracilation and restriction in resting immune 
cells would require enzyme activities that support a high dUTP/TTP ratio and uracil base 
excision and DNA fragmentation. Using sensitive and specific in vitro enzymatic assays 
(Fig. S1A-D)3,9,10, we found that monocytes and monocyte-derived macrophages 
(MDMs)  expressed  high  levels  of  SAMHD1  dNTP  triphosphohydrolase  to  reduce  the 
canonical dNTP pools9,11, undetectable dUTPase activity that allowed dUTP 
accumulation,  and  modest  expression  of  the  UBER  enzymes  uracil  DNA  glycosylase 
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(hUNG)  and  abasic  site  endonuclease  (APE1)  (Fig.  S1E-H).  Although  resting  CD4+  T 
cells also possessed high SAMHD1, hUNG and APE activities, their dUTPase activity 
was  at  least  7-fold  greater  than  MDMs.  LC-MS  analyses  of  the  dUTP  and  canonical 
dNTP levels in resting and activated CD4+ T cells and MDMs revealed that the 
dUTP/TTP  ratio  was  ~20  for  MDMs,  1.1  for  resting  CD4 +  T  cells,  and  <0.05  for 
activated CD4+ T cells (Fig. S1I, J)12,13. 
Total  HIV-1  DNA  isolated  from  in  vitro  infected  MDMs  is  heavily  uracilated.  To 
detect  and  map  uracil  across  the  HIV  genome  we  developed  uracil  excision-digital 
droplet PCR (Ex-ddPCR) (Fig. 1A). Briefly, Ex-ddPCR involves isolation of total DNA 
from HIV infected MDMs, after which half of the sample is treated with UNG to destroy 
template strands that contain uracil (Fig. 1A). Thus, any PCR amplicon that contains one 
or more uracils on each DNA strand is not amplified in the UNG treated DNA sample. 
After performing ddPCR (no UNG treatment) and Ex-ddPCR (UNG pre-treatment), the 
fraction  of  the  amplicons  containing  at  least  one  uracil  on  each  strand  was  calculated 
from the counts of positive droplets for the ddPCR and Ex-ddPCR samples (Fig. 1A). A 
complete description of Ex-ddPCR is found in the Supplementary Information and Fig. 
S2A-E. 
Ex-ddPCR analysis of HIV DNA isolated from single-round infections of activated 
and resting CD4+ T cells and MDMs using a VSVG pseudo-typed HIV strain (HIV NL4.3) 
established that uracilation of viral DNA occurs in MDMs, but not T cells (Fig. 1B). The 
scatter plots and histograms in Figure 1B show that the copy number for viral gag DNA 
isolated  from  MDMs  at  3  days  post-infection  was  3.5-fold  lower  in  the  Ex-ddPCR 
experiment,  showing  that  ~70%  of  gag  amplicons  contained  uracil.  Importantly,  the 
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genomic reference standard RNase P (RPP30) contained no measurable uracil, indicating 
that uracil incorporation is specific to HIV DNA. In contrast, the gag copy number for 
viral DNA collected from activated and resting T cells was the same for both the ddPCR 
and  Ex-ddPCR  reactions  indicating  that  uracil  was  absent  in  viral  DNA  isolated  from 
infected T cells (Fig. 1B).  
To augment Ex-ddPCR, we also applied the next generation sequencing technology 
uracil Ex-Seq to globally map the frequency of U/A pairs across the entire HIV 
genome14.  Ex-Seq  is  similar  to  standard  IIlumina  sequencing  (Seq),  except  that  UNG-
mediated  uracil  excision  is  used  to  destroy  uracil-containing  templates  prior  to  PCR 
amplification.  To  specifically  enrich  HIV-1  sequences,  we  used  5’-biotin  conjugated 
DNA  probes  that  tiled  both  strands  of  the  entire  viral  genome,  yielding  a  10 3-fold 
increase in HIV-derived fragments. Sequencing of viral DNA isolated from MDMs seven 
days after infection with HIV NL4.3 showed uniform coverage across the genome except 
for notably increased reads at the 5´ and 3´-LTR regions, which was equally evident for 
both the Seq and Ex-Seq samples (Fig. 1C). We speculate that the elevated signal in the 
LTRs arises from non-uniform hybridization of the lock-down probes, which is 
normalized when converting the reads to Frac U. The ratio of the normalized sequencing 
reads (Ex-Seq/Seq) thus quantifies the fraction of sequence reads that contained at least 
one uracil on each strand (Fig. 1D). This ratio indicates that on average about 60% of the 
100 bp reads contained uracil and uracilation was fairly uniform across the genome. 
Uracils  do  not  arise  from  APOBEC-catalyzed  cytosine  deamination.  MDMs  have 
previously been shown to have little if any APOBEC DNA cytidine deaminase activity 15, 
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which,  if  present,  would  introduce  uracils  via  a  parallel  cytidine  deamination  pathway. 
We confirmed that APOBEC activity was not important in control experiments described 
in the Supplemental Information (Fig. S3A-F).  We also established that the level of 
viral  DNA  uracilation  could  be  greatly  attenuated  by  increasing  the  intracellular  TTP 
levels by adding thymidine to the culture media (Fig. S3G-I). These results are consistent 
with our proposal that the uracils arise from dUTP utilization by reverse transcriptase. 
Integrated  proviruses contain  abundant  uracils.  The  above  analyses  report  on  both 
integrated and unintegrated viral DNA.  However, the Ex-Seq experiment also provides 
specific information on the uracilation status of integrated proviruses and their genomic 
sites of integration (Fig. 1E). Sequence reads from integrated proviruses are 
unambiguously  assigned  by  the  presence  of  viral  LTR  and  human  genomic  sequences 
(“discordant  pairs”).  Over  4000  discordant  pairs  were  identified  per  million  HIV  reads 
for the Seq sample, which was reduced by about 60% for the Ex-Seq sample (Fig. 1E). 
This  level  of  uracilation  is  similar  to  that  of  the  total  HIV  DNA  and  reinforces  our 
previous assertion that uracils can persist in proviruses when nuclear hUNG2 expression 
is low3. 
Identification of restrictive and permissive MDM subpopulations. During HIV 
infection  of  MDMs  ~10%  of  the  infected  MDMs  were  positive  for  GFP  fluorescence 
after  a  single-round  infection  with  HIVNL4.3   (Fig.  2A), which  remained  constant  from 
about 7 to 30 days after infection and did not vary when the MOI was varied in the range 
0.1-10 (Fig. S4). This result led us to suspect that the MDM population consisted of a 
phenotypic mixture with different susceptibilities to HIV infection. (We note that higher 
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MOIs are typically used in our experiments to obtain reasonable viral copy numbers in 
the GFP - population). Accordingly, we used GFP fluorescence to sort HIV NL4.3 infected 
MDMs into 99% pure GFP positive and negative populations (Fig. S5). Digital droplet 
PCR  measurements  showed  that  the  copy  number  of  early  viral  DNA  products  in  the 
GFP- population (detected using a gag-specific PCR primer) was about 7-fold lower than 
the GFP+ population at one-day post infection (~2 versus 14 copies/cell, Fig. 2B).  This 
result  suggested  that  viral  infection  was  hindered  at  the  entry  and/or  early  reverse 
transcription  steps  in  the  GFP-  population.  Using  Alu-gag  nested  qPCR  to  measure 
proviral  copies16,  we  found  that  the  GFP-  population  contained  only  1%  of  the  copies 
seen in the GFP+ MDMs (Fig. 2C).  The large decrease in copy number between the early 
DNA intermediates and the provirus stage indicates that a potent pre-integration 
restriction mechanism is present exclusively in the GFP- population. 
Viral uracilation is exclusive to GFP - MDMs. We used infections with a replication-
competent  virus  HIV SF162  to  further  elucidate  the  characteristics  of  the  two  MDM 
populations.  First,  the  infected  MDMs  were  sorted  into  GFP  positive  and  negative 
populations at one-day post infection.  The cells were then cultured for 30 days and at 
one, seven, 14, and 30 days post-sorting we measured proviral copy numbers, the fraction 
of uracil-containing proviruses, and the levels of viral growth by ELISA for HIV-1 p24 in 
the culture supernatants for each cell population (Fig. 2D, E). Both the GFP positive and 
negative populations showed high levels of viral gag DNA products at day one (red circle 
and blue square, Fig. 2D). The GFP+ population was characterized by efficient 
integration of viral DNA products and a high proviral copy number that remained stable 
for 14 days, before increasing by ~4-fold, which we attribute to secondary infection by 
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released  viruses  (white  bars,  Fig.  2D).  In  contrast,  the  GFP -  population  had  a  low 
efficiency of integration exemplified by a 50-fold reduction in copy number between the 
early gag DNA products and proviruses (black bars, Fig. 2D). Unlike the GFP + cells, the 
copy number in the GFP- population decreased 20-fold between days seven and 14 before 
returning  to  the  day  seven  level  at  30  days.  We  attributed  the  increase  to  secondary 
infection by released virus particles because it was not observed in single-round 
infections. We established that HIV NL4.3, HIVSF162, and HIV BAL viral strains and MDMs 
isolated from different donors behaved similarly (Fig. S6A-E), and that the results were 
independent of whether differentiated MDMs were obtained using adherence, M-CSF, or 
GM-CSF protocols (Fig. S6F-H). 
The most striking difference between the two MDM populations was that the minor 
GFP+ population had no detectable proviral uracils, while ~90% of the proviral copies in 
the major GFP - fraction contained uracil at day one (Fig. 2D). The fraction of proviral 
copies that were uracilated (Frac U) decreased from 0.77 to 0.23 between days 7 and 14 
before rising to 0.55 at day 30 (presumably due to continuing infection).  We explored 
the  mechanistic  basis  for  the  differences  in  viral  uracilation  between  the  two  MDM 
populations by measuring dUTPase, hUNG2, and SAMHD1 activities and the dUTP/TTP 
ratio in the cell extracts (Table S1). The only salient difference in these parameters was 
the  20-fold  lower  dUTP/TTP  ratio  in  the  GFP+  MDMs,  which  could  partially  or  fully 
account for the absence of uracils in these cells. 
Consistent with their larger proviral copy numbers, the GFP + MDMs produced 100 
to 1000 times more p24 than the GFP - MDMs and the levels were fairly constant over a 
30-day period (Fig. 2E). In contrast, the GFP - MDMs showed a 10-fold decrease in p24 
79
levels  between  day  7  and  14  (Fig.  2E),  which  coincides  with  the  20-fold  reduction  in 
proviral  copy  number  in  the  same  time  period  (Fig.  2D).  The  expression  of  detectable 
levels of p24, but not GFP, in the GFP - MDMs suggests that truncated viral RNAs are 
being expressed that extend through the p24 coding sequence, but not GFP.  
Viral uracilation is modulated by hUNG2 activity. We previously reported that in the 
HT29 model cell system nuclear hUNG2 activity was the primary determinant of whether 
uracilated viral DNA survived or persisted in cells 3. To confirm this result in MDMs we 
took  advantage  of  viral  protein  R  (vpr),  which  interacts  with  hUNG2  and  induces  its 
degradation through the assembly with the DDB1-CUL4 ubiquitin ligase complex 17. We 
surmised  that  infection  of  MDMs  with  a  viral  construct  without  vpr  (HIVNL4.3Δvpr) 
would lead to increased hUNG2 activity, fewer proviral copies, and lower uracil levels in 
proviral DNA. 
We determined that the nuclear (hUNG2) and mitochondrial (hUNG1) isoforms were 
detectable by western blotting (Fig. S8) and that HIV NL4.3Δvpr virus did not express vpr 
(Fig.  3A).  Infections  of  MDMs  with  HIVSF162  and  HIVNL4.3Δvpr  showed  that  between 
one  and  seven  days  post-infection  the  hUNG2  nuclear  isoform  selectively  disappeared 
with HIV (vpr+), but not HIVNL4.3Δvpr (Fig. 3A)17. As expected, infection with 
HIVNL4.3Δvpr  reduced  the  overall  proviral  copies  present  in  the  mixed  population  of 
GFP+  and  GFP-  MDMs  (Fig.  3B),  which  can  be  attributed  to  any  of  the  known  pro-
infective  functions  of  vpr17.  The  most  instructive  result  was  that  in  the  absence  of  vpr 
fewer  proviruses  contained  uracil  (Frac  U  decreased  by  2-fold)  (Fig.  3C).  This  result 
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specifically  reports  on  vpr-induced  depletion  of  hUNG2  activity  in  the  GFP-  MDMs 
because uracils are only present in GFP - MDMs and hUNG is the only glycosylase that 
acts on U/A base pairs in DNA18.
Uracilated proviruses produce fewer viral genomic RNAs. We investigated whether 
the  presence  of  uracil  in  proviral  DNA  affected  the  copy  number  of  extracellular  viral 
genomic RNAs (EVRs) present in supernatants of infected MDMs cultured in standard 
growth  media  or  media  supplemented  with  IFNγ  or  IL-4  (Fig.  4A).  The  EVR  copies 
present  in  the  supernatants  of  GFP+  and  GFP-  MDMs  were  measured  using  reverse 
transcriptase quantitative PCR (RT-qPCR) at three days post-cytokine stimulation. These 
cytokines were of interest because they stimulate macrophage differentiation into 
classical pro-inflammatory (M1) and anti-inflammatory (M2) polarization states, 
respectively19.  We  found  that  EVR  copies  were  about  100-fold  lower  for  the  GFP - 
population  than  the  GFP+  MDMs,  regardless  of  cytokine  stimulation  and  that  IFN γ 
stimulation reduced the EVR copy number in both MDM populations (Fig. 4B). 
Extracellular  viral  RNAs  (EVRs)  have  more  mutations  than  uracilated  proviral 
DNA. Limiting dilution clonal sequencing was performed on EVRs produced from sorted 
GFP- and GFP+ MDMs at three days post-stimulation20,21, revealing surprising 
differences  in  viral  single-point  mutation  frequencies  for  these  populations  (Fig.  4C). 
Regardless of cytokine stimulation, the GFP + population showed no detectable mutations 
in  the  roughly  12,000  total  bases  of  the  V3/V4  variable  region  of  env  that  were 
sequenced.  In  contrast,  the  GFP-  population  showed  a  1.2%  basal  mutation  frequency, 
which responded differently to IFNγ and IL4 stimulation:  IFNγ stimulation increased the 
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frequency by 2-fold and IL4 decreased it significantly (Fig. 4C). These results suggest 
that the cytokine environment of an in vivo infected macrophage will influence the fate of 
uracilated proviruses. In contrast to the mutated env sequences, the LTR region of EVRs 
produced from the GFP - cells was devoid of detectable mutations after sequencing 7,392 
total  bases  (Table  S2),  which  may  reflect  selection  for  expression  of  transcription 
competent  LTR  sequences.  The  absence  of  mutations  in  the  env  and  LTR  regions  of 
EVRs  isolated  from  the  GFP+  MDM  cultures,  as  well  as  the  LTR  region  of  EVRs 
obtained from the GFP - culture supernatants, virtually eliminates the possibility that the 
observed mutations in env arise from PCR or sequencing errors.  
The frequencies of single-base transition, transversion, and insertion/deletion 
mutations  within  the  env  region  of  EVRs  produced  from  IFNγ,  IL4  and  unstimulated 
GFP- cells  are  shown  in  Fig.  4C.  Analysis  of  the  observed  Gà A  (+)  strand  mutations 
using Hypermut 2.0 22 indicated that the sequence dependence and frequencies were not 
attributable to APOBEC deaminase activity on the viral (-) strand cDNA23. The 
remaining RNA (+) strand mutations were primarily single base changes mostly 
comprised of Aà G, Aà C, and Tà C transitions and transversions (Fig. 4D,E), but also 
a few short 2-3 nucleotide insertions or deletions. 
Targeted  sequencing  of  the  env  amplicon  in  uracilated  viral  DNA  isolated  from 
GFP-  MDMs  at  day  fourteen  post-infection  in  the  absence  of  cytokine  stimulation 
revealed  a  <0.007%  mutation  frequency  in  the  V3/V4  variable  region,  which  may  be 
contrasted with the 1.2% frequency in EVRs produced from the same cell culture (most 
viral  DNA  is  integrated  at  day  fourteen).  This  result  suggests  that  the  EVR  mutations 
arise from transcriptional errors by RNA polymerase II (RNAP II). Such mutations may 
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derive  from  encounter  of  the  polymerase  with  either  uracils  or  repair  intermediates 
resulting from uracil excision (see Discussion). Illumina next-generation sequencing data 
covering the entire viral DNA genome (obtained from total HIV NL4.3 viral DNA isolated 
from  a  mixed  population  of  MDMs  at  day  seven  post-infection  in  the  absence  of 
cytokines) confirmed the low mutation frequency determined from targeted sequencing 
of the env V3/V4 variable region (see Data Access information).  
To  explore  whether  the  mutation  signature  of  uracilated  viral  DNA  products  and 
viral genomic RNA sequences derived from infected MDMs were distinct from T cells, 
we  infected  activated  CD4+  T  cells  with  HIVBAL  virions  produced  from  donor  cells 
expressing  endogenous  levels  of  APOBEC3G  (A3G)  (Supplemental  Methods).  The 
infection was kept to a single round by inclusion of the entry inhibitor enfuvirtide 24, and 
the V3/V4 env region of 14 proviruses were sequenced. The proviral sequences derived 
from infected T cells had a much higher mutation frequency (~1%) than uracilated viral 
DNA  in  MDMs  (<0.007%),  but  the  frequency  was  similar  to  the  EVRs  expressed  by 
infected GFP- MDMs cultured in the absence of cytokines (1.2%, Fig. 4C). 
The  mutation  spectrum  of  proviral  DNA  isolated  from  T  cells  differed  from  the 
EVRs produced from MDMs (Fig. 4E). The distinguishing proviral mutations found in T 
cells are elevated Cà T transitions and Tà G transversions, while the viral RNA 
sequences  derived  from  MDMs  are  distinguished  by  elevated  Aà C  transversions  and 
Tà C  transitions  (Fig.  4E).    We  note  that  previous  studies  have  established  that  host 
RNAP II contributes little to HIV sequence evolution in T cell infections and that errors 
during reverse transcription are the predominant diversification mechanism 25. This does 
not appear to hold for in vitro infection of MDMs. 
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Uracilated proviruses produce replication competent HIV. To measure the levels of 
functional  progeny  viruses  that  emerged  from  infected  MDMs  in  the  absence  and 
presence  of  cytokine  stimulation  we  followed  the  approach  outlined  in  Figure  5A. 
MDMs infected with HIV SF162 were first sorted based on GFP fluorescence at one-day 
post-infection.  The  sorted  GFP  positive  and  negative  cells  were  divided  into  three 
cultures that were stimulated with IFN γ, IL4, or no treatment. After three days the MDM 
producer cultures were analyzed with respect to (i) gag DNA copy number as a surrogate 
for  total  viral  DNA  present  (Fig.  5B),  (ii)  integrated  proviral  DNA  copy  number  (Fig. 
5C),  (iii)  the  fraction  of  proviruses  containing  uracil  (Fig.  5D),  and  (iv)  p24  levels  in 
culture  supernatants  as  a  surrogate  for  progeny  virus  output  (Fig.  5E).  The  virus-
containing MDM culture supernatants were removed at three days post-stimulation (dps), 
normalized to p24 and added to cultures of CEMx174 target cells. After three days, the 
proviral copy number per 106 target cells was measured (Fig. 5F).  
Independent  of  stimulation,  the  GFP-  MDM  producer  cells  showed  lower  copy 
numbers  of  gag  and  proviral  DNA  (~20  and  104-fold)  and  p24  levels  (100-fold),  as 
compared to GFP+ MDMs26. IFNγ or IL4 stimulation had little effect on gag and proviral 
DNA copy numbers in both MDM producer populations (Fig. 5B,C), but IL4 induced a 
modest  decrease  in  the  fraction  of  proviruses  that  contained  uracil  at  three  days  post 
stimulation (Fig. 5D). For both MDM types, the addition of either cytokine resulted in a 
reduction in p24 production, with IFNγ showing the largest effect relative to no 
stimulation  (~10-fold  decrease)  (Fig.  5E,F).  Despite  the  much  lower  levels  of  virus 
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produced from GFP - MDM producer cells, the harvested viruses derived from uracilated 
proviruses were capable of infecting CEMx174 target cells (Fig. 5G). 
Uracils  are  present  in  HIV-1  DNA  from  peripheral  blood  monocytes  of  virally 
suppressed  donors.  To  test  whether  HIV-1  DNA  isolated  from  infected  individuals 
contained  detectable  levels  of  uracil  we  purified  resting  CD4+  T  cells  and  monocytes 
from bulk peripheral blood mononuclear cells (PBMCs) of six participants suppressed on 
antiretroviral  therapy  (ART).  Highly  purified  populations  of  resting  CD4+  T  (>95%) 
cells and monocytes (>98%) were obtained and quantified by flow cytometry (Fig. S8A-
C). ddPCR and Ex-ddPCR were used to quantify HIV DNA and measure the fraction of 
the viral pol amplicons that contained uracil (Fig. 6A,B) 27. HIV DNA levels in resting 
CD4+ T cells were generally higher and more variable than those measured in monocytes 
(geometric  mean  values  of  526  copies/106  T  cells  and  47  copies/106  monocytes)  (Fig. 
6A)28,29. Consistent with in vitro measurements (Fig. 1B), we found no detectable uracil 
(Frac  U)  in  HIV  DNA  isolated  from  resting  CD4+  T  cells,  but  five  of  the  six  donor 
monocyte samples contained detectable uracils. The fraction of uracil-positive pol 
amplicons  was  in  the  range  20  to  80%  for  the  five  patient  samples  (Fig.  6B).  The 
observation that viral DNA uracilation is specific to monocytes and macrophages 
provides an unambiguous marker of its origins and excludes contaminating T cell DNA 
as a possible source. 
 We  also  obtained  access  to  cryopreserved  bronchial  alveolar  lavage  (BAL)  and 
PBMC isolates from a single HIV-1 infected donor that were collected prior to initiation 
of ART and six months after ART therapy and performed a similar analysis (Fig. 6B).  
Viral  DNA  from  highly  purified  monocytes  was  tested,  as  well  as  bronchial  alveolar 
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lavage (BAL) samples that consisted of >95% alveolar macrophages (AMs). Using the 
Ex-Alu-gag PCR method for detecting proviral DNA we found that ~40% (monocytes) 
and  80%  (alveolar  macrophages)  of  the  Alu-gag  amplicons  were  positive  for  uracils. 
Similar  levels  of  uracils  were  detected  in  pre-  and  post-ART  BAL  isolates  (Fig.  6B).  
Although a stable reservoir for HIV is primarily located in resting CD4+ T cells, these 
results  suggest  that  HIV  DNA  residing  in  monocytes/alveolar  macrophages  comprises 
another source for viral rebound after discontinued therapy, consistent with other 
reports30.
Discussion  
Host  cell  DNA  repair,  HIV  restriction,  persistence  and  mutagenesis.    Previous 
literature contains diverse and sometimes conflicting data on the role of dUTP and host 
cell uracil DNA glycosylase in HIV infection [reviewed in Weil et al. 3]. Our key finding 
that MDMs consist of two distinct populations with respect to the uracilation phenotype 
likely explains why this potent restriction pathway has remained largely elusive.  
The established elements of this pathway are depicted in Figure 6C.  Upon entry 
into the macrophage, reverse transcriptase (RT) encounters a nucleotide pool 
environment that favors the incorporation of dUTP into HIV DNA products 
predominantly in the form of U/A base pairs. The high ratio of dUTP/TTP is maintained, 
at  least  in  part,  by  the  low  levels  of  dUTPase  expression  combined  with  the  high 
expression levels of SAMHD1 in macrophages. Uracilation of the viral DNA can proceed 
to high levels in the cytoplasmic compartment because the UBER machinery is 
sequestered in the nucleus. However, when the heavily uracilated HIV DNA enters the 
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nucleus  it  is  attacked  and  fragmented  by  nuclear  UBER  enzymes.  Fragmentation  is 
initiated  by  hUNG2  uracil  excision,  and  is  likely  followed  by  abasic  site  excision  by 
human abasic site endonuclease (APE1 or APE2) (Fig. S1) 31,32. We estimate, based on 
comparing  the  measured  levels  of  early  and  proviral  DNA  levels  in  the  GFP-  MDMs 
(Fig. 2), that ~99% of the viral DNA is destroyed before the integration step. The viral 
DNA  products  that  escape  initial  restriction  can  integrate  into  the  host  cell  DNA  and 
follow different fates that are discussed below (Fig. 6C). 
We  speculate  that  lethal  mutagenesis,  functional  genome  variation,  or  faithful  repair 
could  result  from  host  enzyme  processing  of  uracilated  proviruses.  In  non-dividing 
MDMs,  we  found  that  uracilated  proviruses  contained  few  mutations  yet  gave  rise  to 
mutated  viral  genomic  RNAs  (Fig.  4D).  Although  it  is  tempting  to  attribute  these 
mutations to RNAP II transcriptional errors as it encounters uracil on the template DNA 
strand,  RNAP  II  shows  high-fidelity  incorporation  of  A  opposite  to  U  during  in vitro 
transcription25.    Moreover,  many  aspects  of  the  mutation  spectrum  in  Fig.  4E  are  not 
reconcilable with RNAP II incorporating incorrect bases opposite a template U (although 
the frequent A à G transitions may be explained by the potential of U to pair with A or 
G)33. The actual error mechanism is likely to be much more complex given that 
transcription coupled repair is expected to generate abasic sites, strand breaks, and even 
gaps when densely spaced uracils are excised. In this regard, RNAP II is known to stall at 
isolated abasic sites during in vitro transcription and could also misincorporate various 
ribonucleotides at such sites in vivo34. 
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The observation that proviral DNA is relatively mutation free, while the RNA is not, 
strongly  suggests  that  repair  intermediates  generated  during  transcription  by  the  host 
UBER pathway are most often repaired to restore the proviral coding sequence. Faithful 
repair  could  involve  the  reincorporation  of  U  opposite  to  A  due  to  the  perturbed 
nucleotide  pools,  or  the  introduction  of  T.  The  observation  that  RNA  mutations  were 
increased upon stimulation with the inflammatory cytokine IFNγ, and nearly absent in the 
presence of the anti-inflammatory cytokine IL4, indicates that the transcriptional 
programs induced by these cytokines are highly relevant to the outcome. Although errors 
introduced  by  IFNγ  stimulation  may  frequently  lead  to  non-functional  viral  genomes, 
they will also allow the viral DNA sequence to evolve rapidly in the absence of reverse 
transcription.  Replication-competent  viruses  that  emerge  would  then  under  go  fitness 
selection in the host. These potential outcomes make UBER a double-edged sword with 
respect to propagation of viral infection. 
Uracil has never been considered an epigenetic base like 5-substituted cytosines because 
of  its  low  abundance  in  genomes  and  because  the  detection  of  U/A  base  pairs  eludes 
standard  sequencing  methods.    Nevertheless,  uracil  has  the  potential  to  alter  DNA 
structure and dynamics 35, which could affect site recognition by transcription factors or 
other DNA binding proteins. There is a growing body of evidence indicating that uracil 
can exert significant effects on protein binding to DNA.  These findings include (i) our 
previous  report  that  multiple  uracils  silenced  transcription  from  both  HIV-1  LTR  and 
CMV  promoters  in  a  cell  line3,  (ii)  uracils  within  the  origin  of  replication  in  HSV-1 
perturb  the  binding  of  HSV-1  origin  binding  protein36,  (iii)  U/A  pairs  disrupt  AP-1 
transcription factor DNA binding37, (iv) singly uracilated DNA disrupts RNase H splicing 
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specificity during reverse transcription 38, (v) U/A pairs perturb maintenance of telomere 
length in B cells by disruption of sheltrin binding 39, and (vi) one or two U/A base pairs 
within  the  specific  cleavage  site  of  some  restriction  enzymes  prevents  DNA  strand 
cleavage40.  In addition, the abasic site product of uracil excision is known to exert a large 
negative effect on transcription41, as would any mutations in transcription factor 
recognition sequences arising from error prone repair of excised uracils 42,43. Combined, 
these potential effects of U/A pairs could profoundly silence HIV gene expression. 
Historically, macrophages have been controversial targets for HIV infection 44. However, 
these long-lived cells have a significant impact on HIV-1 infection because they persist 
for months after initial infection 45, continue to produce infectious virus particles for their 
entire  lifetime46,  and  provide  a  drug  tolerant  environment  for  HIV  propagation47,48). 
Moreover,  their  residence  within  tissues  that  have  poor  drug  penetrance  (lung,  brain, 
gut)30,  has  led  to  an  increased  interest  in  their  potential  role  in  the  establishment  and 
persistence of HIV infection.  
One key question arising from our results is the lifetime of uracils within proviral 
DNA in vivo. The detection of abundant viral uracils in monocytes isolated from HIV-1 
infected individuals who showed full viral suppression from ART, indicates that 
uracilation  occurs  in vivo  during  the  normal  course  of  viral  infection  of  myeloid  cells. 
The  fairly  short  several  day  half-life  of  blood  monocytes  suggests  that  uracilated  viral 
DNA  within  these  cells  arises  from  a  recent  infection,  perhaps  by  passage  of  the 
monocyte through a tissue reservoir containing virus producing cells 28. Such an infection 
pathway could involve a canonical CCR5-dependent viral entry mechanism or a recently 
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described pathway involving phagocytosis of infected T cells by macrophages50. 
However, the high efficiency of ART and the low levels of infected T cells using current 
treatment  regimes  make  the  phagocytosis  pathway  for  monocyte  infection  seem  less 
plausible for our aviremic patient samples. Finally, the requirement for dUTP 
incorporation  during  reverse  transcription  virtually  excludes  the  possibility  that  the 
infected monocytes containing uracilated DNA arose from latently infected myeloid stem 
cells, because monocyte differentiation does not involve reverse transcription and 
genomic  DNA  replication  does  not  involve  accumulation  of  detectable  uracils  (Fig. 
S8H). 
A further ramification of these data is that some uracilated proviruses may persist 
for  the  entire  lifetime  of  a  macrophage  due  to  protection  within  highly  compacted 
chromatin, which is highly resistant to UBER 35. Under such circumstances, the potential 
time  scale  for  uracil  persistence  could  be  years  based  on  the  findings  that  replication-
competent viruses have been detected in brain microglial cells of patients even after years 
of viral suppression using ART 51,52. If U/A pairs are found to down regulate viral gene 
expression through chromatin stabilization or by weakening the binding of transcription 
factors,  some  proviruses  could  remain  transcriptionally  silenced  for  years  and  then 
become activated when appropriate stimulatory conditions are present. 
Experimental Procedures 
Study subjects   
This study was approved by the Johns Hopkins Institutional Review Board and written 
informed consent was provided by both HIV-infected and healthy individuals 
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(IRB00038590). Peripheral blood was obtained from healthy volunteers and ART 
suppressed patients with viral loads <20 copies HIV-1 RNA/mL. Monocytes and resting 
CD4+  T  cells  were  obtained  from  donor  PBMCs  as  described  in  the  Supplemental 
Methods and the purity of the cell types was determined by flow cytometry. 
Viruses 
Pseudotyped HIV-1 virions (HIVNL4.3 and HIVSF162) were generated as previously 
described3. HIVNL4.3(Δvpr) and HIVNL4.3(Δvif) mutant virus constructs were generated by 
site-directed mutagenesis of pNL4-3-ΔE-eGFP. Primers used for site-directed 
mutagenesis can be found in Supplemental Information (Table S3). 
Western blot analyses 
Protein extracts were prepared from MDMs that had been mock treated or infected with 
HIVNL4.3(wt) and HIV SF162 or mutant viruses HIV NL4.3(Δvpr) and HIV NL4.3(Δvif). Protein 
extraction  was  performed  using  CelLytic  M  reagent  (Sigma-Aldrich)  according  to  the 
manufacturer’s instructions. Protein concentration was determined by the Bradford assay 
(BioRad). 
Excision digital droplet PCR (Ex-ddPCR)  
To determine the uracil status of viral DNA a modified digital droplet PCR (Ex-ddPCR) 
method  was  developed  by  inserting  a  pre-digestion  step  using  UNG  (Fig.  1).  Total 
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genomic  DNA  was  isolated  using  a  QIamp  DNA  extraction  kit  (Qiagen)  according  to 
manufacturer’s protocol and processed as described in the Supplemental Methods.  
Ex-Alu-gag nested qPCR 
To specifically measure fractional uracilation of proviral DNA we used a modification of 
the Alu-gag nested qPCR approach, in which an UNG digestion step is inserted before 
the initial PCR amplification (Ex-Alu-gag nested qPCR)3,16. 
Fluorescence activated cell sorting 
In preparation for cell sorting studies, MDMs infected with GFP-reporter virus (HIV NL4.3 
or  HIVSF162)  were  washed  twice  with  Hank’s  balanced  salt  solution  (HBSS)  and  then 
detached by incubating with Accutase (Cell Technologies) for 30 min at 37 °C. MDMs 
were resuspended at 5x106/mL in 1x HBSS (pH 7.2), 5 mM EDTA and 0.5% BSA. Prior 
to sorting, cell suspensions were passed through a 35 mm nylon mesh (BD Biosciences) 
and propidium iodide added to gate out dead cells. Sorting was performed on a MoFlo 
Sorter using a 100 µm nozzle and the sort purify 1 mode.  
Viral RNA isolation and limiting dilution sequencing 
Viral RNA isolated from p24-positive wells was DNaseI-treated (Invitrogen) and reverse 
transcribed using the qScript cDNA synthesis kit (Quanta Biosciences).  PCR 
amplifications were performed using limiting dilution conditions as previously 
described21. 
Statistical Analyses 
Data were analyzed for statistical significance (HIV copy number and Frac U DNA) by a 
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two-tailed Student’s t test for independent samples using GraphPad Prism. p<0.05 was 
deemed significant.  
Data Access 
Raw and processed sequencing data files (FASTAQ) from this study have been deposited 
to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)53 
under  accession  number  GSE76091.  A  reproducible  software  pipeline  for  analysis  of 
Excision-seq data is available at https://github.com/hesselberthlab/stivers-hiv.    
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Figure 3.1 Ex-ddPCR to determine the uracil content of the HIV gag gene. (A) Total 
DNA  is  isolated  from  immune  cells  and  either  digested  by  UNG  to  degrade  uracil 
containing DNA or mock digested for total amplifiable DNA in the sample. The output 
(Frac UDNA)  represents  the  fraction  of  amplified  DNA  copies  containing  at  least  one 
uracil on each DNA strand. Signal is normalized to a genomic reference copy standard 
(RPP30)  that  does  not  contain  uracil.  (B)  Activated,  resting  CD4+  T  cells  and  MDMs 
were infected in vitro with HIV NL4.3 virus and uracil content was measured 3 days post-
infection (dpi) using primers that targeted the gag region. The data (+/- UNG digestion) 
are  shown  as  scatter  plots  and  histograms.  (C)  Normalized  coverage  of  the  HIVNL4.3 
genome positive strand in Excision-seq libraries prepared from total cellular DNA at 7 
days post-HIV infection. (D) Fraction of the reads in panel C that contained uracil (Frac 
U). (E) Discordant read pairs between HIV and human DNA present in Ex-seq libraries 
prepared from total cellular DNA at 7 days post-HIV infection. The number of discordant 
reads obtained by Ex-seq in the absence and presence of UNG digestion are shown as 




Figure  3.2  MDMs  consist  of  two  distinct  cell  populations  with  respect  to  viral 
infection.  (A)  Only  about  10%  of  HIVNL4.3  infected  MDMs  expressed  virally  encoded 
GFP as determined by flow cytometry. (B) ddPCR measurements of the copy number of 
reverse transcription intermediates (RTIs) for infected GFP - (white bars) and GFP+ (green 
bars)  MDMs.  (C)  Alu-gag  nested  qPCR  measurement  of  the  provirus  copy  number  in 
GFP- and GFP + MDMs. (D) Measurement of provirus copy number and uracil content 
over the course of a 30-day multi-round infection with HIVSF162. (E) ELISA 
measurements of viral p24 protein levels in GFP - and GFP+ MDMs over the course of a 





































































































































Figure 3.4 Impact of uracilation and cytokines on viral genome sequence.  
(A) Experimental protocol. (B) Quantitative reverse transcriptase-PCR (qRT-PCR) was 
used to determine the copy numbers of extracellular viral RNA in cell supernatants from 
sorted  GFP+  (green  bars)  and  GFP-  (white  bars)  MDMs  with  and  without  cytokine 
stimulation.  (C)  Summary  of  mutations  from  limiting–dilution  clonal  sequencing  of 
extracellular  viral  RNAs  obtained  from  infected  GFP-  MDMs  under  different  growth 
conditions.  The  mutation  frequencies  (point  mutations  per  total  nucleotides  sequenced) 
were  obtained  from  a  ~500  bp  amplicon  of  the  env  gene.  ND;  not  detected.  (D) 
Representative  env  sequences  of  extracellular  viral  RNAs  produced  by  GFP -  sorted 
MDMs. The top sequence is for the HIVSF162 strain used to infect the MDMs 
(HIVSF162_env_ref). Boxed regions at the protein and nucleotide sequence level show 
the  mutation  spectrum  within  the  CD4-associated  and  co-receptor  binding  sites.  (E) 
Breakdown of point mutations for viral RNA produced from infected MDMs and proviral 




Figure 3.5 Effects of cytokine stimulation on viral transmission in GFP sorted MDM 
populations. (A) Experimental approach. (B) MDMs infected with HIV SF162 were sorted 
into GFP+ (green bars) and GFP- (white bars) populations and analyzed with respect to 
gag copy number (dps; days post stimulation). (C) Provirus copy numbers for each MDM 
population  were  measured  using  Alu-gag  nested  qPCR  at  3  dps.  (D)  The  fraction  of 
proviral  DNA  copies  containing  uracil  was  measured  using  Ex-Alu-gag  nested  qPCR.  
ND; not detected. (E) Viral growth kinetics of sorted MDM populations.   (F) Levels of 
virus  in  culture  supernatants  of  GFP+  and  GFP-  MDM  producer  cells  were  measured 
using p24 ELISA. (G) Viral supernatants from each MDM treatment were normalized to 
p24 levels and used to infect naïve CEMx174 target cells. Provirus copies were measured 
using Alu-gag qPCR.  The results are normalized to one million target cells.  Errors are 
shown as the mean ± SD.  
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levels of uracil in HIV DNA. (A) Resting CD4+ (rCD4+) T cells and monocytes were 
purified by negative bead selection from bulk PBMCs obtained from six ART-suppressed 
individuals.  Total  HIVpol  DNA  was  quantified  using  Ex-ddPCR.  Copy  numbers  were 
normalized to the human RPP30 gene to give an estimate of HIV copies/10 6 cells. (B) 
The uracilated fraction of HIV pol DNA copies derived from monocytes and rCD4+ T 
cells  was  measured  using  Ex-ddPCR.  Total  genomic  DNA  was  also  isolated  from 
matched,  cryopreserved  PBMCs  and  bronchial  alveolar  macrophages  (AM)  obtained 
from a single donor both pre-ART (green circle) and post-ART (yellow circle), 
(***p<0.001). Donor 4 had no detectable uracil (pol) and was excluded from this plot. 
(C) Infection of MDMs by HIV-1 and possible fates of uracilated viral DNA products 
(see text).  
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Figure 3.7 Profiling enzyme activities and dNTP pool levels in immune target cells of 
HIV.  Extracts from each indicated cell type were obtained as described in Methods. (A) 
Deoxyuridinetriphosphate hydrolase (dUTPase) activity was measured by monitoring the 
hydrolysis of dUTP to dUMP via PEI-cellulose TLC. Specificity was determined using a 
potent dUTPase inhibitor (compound 26 in16). (B) SAMHD1 triphosphohydrolase 
activity  was  determined  by  C18  RP-TLC  based  assay  using  8-3H-labeled  dGTP  as  the 
substrate. Specificity for SAMHD1 was determined using the inhibitor pppCH 2dU. The 
mobilities of the substrate (dGTP) and product nucleoside (dG) are marked. (C) 
Endogenous uracil DNA glycosylase (hUNG) activity (combined hUNG1 and hUNG2) 
was  determined  using  a  fluorescein-labeled  DNA  substrate  that  shows  an  increase  in 
fluorescence  upon  uracil  excision.  Specificity  for  hUNG  activity  was  determined  by 
addition of the uracil DNA glycosylase inhibitor protein (UGI). (D) Apyrimidinic 
endonuclease  (APE1  or  2)  activity  was  measured  using  a  fluorescein-labeled  duplex 
DNA  containing  a  single  abasic  site  that  increases  in  fluorescence  upon  endonuclease 
cleavage.  (E)  dUTPase  activity.  (F)  SAMHD1  activity.  (G)  hUNG  activity.  (H)  APE 
activity. (I) Measurement of deoxyribonucleotide (dNTP) pool levels were determined by 
an  LC-MS  method.  (J)  MDMs  contain  a  high  ratio  of  dUTP/TTP  ratio  compared  to 
resting and activated CD4+ T cells.  Abbreviations: rCD4+, resting CD4+ T cell; aCD4+, 
PHA  activated  CD4+  T  cell;  MDM,  monocyte-derived  macrophage.  See  Supplemental 





Figure  3.8.  In  vitro  generated  calibration  curves  for  evaluating  uracil  content  in 
DNA  amplicons  and  single-round  HIV  infections  of  cultured  MDMs.  (A)  ddPCR 
Primer  and  probe  locations  relative  HIV  genome  (HIVNL4.3).  (B)  Generation  of  uracil 
containing duplex DNA of increasing length and ratio of dUTP/TTP was achieved by in 
vitro  DNA  polymerization  using  Taq  polymerase  in  the  presence  of  various  ratios  of 
dUTP/TTP.  These  DNA  standards  (79  to  471  bp)  were  analyzed  by  the  Ex-ddPCR 
method as indicated. (C) The fraction of the DNA amplicons that contained detectable 
uracil (Frac U) increased with DNA amplicon length as well as the dUTP/TTP ratio used 
in  the  initial  DNA  synthesis.  (D)  In  single-round  infections  of  a  mixed  population  of 
MDMs  with  HIVNL4.3,  the  copy  number  of  early,  middle  and  late  viral  cDNAs  were 
measured over a 30-day culture period using primers specific to different regions of the 
viral genome (see above). The copy number is normalized to one million MDM target 
cells. (E) Uracil content was measured in each HIV DNA population using Ex-Alu-gag 
nested qPCR. 
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(A3A) and A3G in MDMs over a 30-day culture period after infection was consistently 
low. (D) Flow cytometry measurements established that viral GFP expression is 
decreased  ~5-fold  upon  infection  with  HIV NL4.3(Δvif)  as  compared  to  HIV NL4.3.  (E) 
Reverse transcription intermediates (RTIs) and provirus DNA levels are generally 
reduced  for  infection  of  MDMs  with  HIVNL4.3(Δvif).    Viral  DNA  copy  numbers  were 
measured by ddPCR (gag amplicon) and Alu-gag nested qPCR, respectively. (F) Ex-Alu-
gag  nested  qPCR  showed  that  the  fraction  of  viral  DNA  copies  containing  uracil  is 
unaffected  when  MDMs  are  infected  with  HIVNL4.3(Δvif).  (G)  Supplementation  of  the 
culture  media  with  5  mM  thymidine  has  no  significant  effect  on  GFP  expression.  (H) 
Cultures supplemented with 5 mM thymidine showed a 5-fold increase in provirus copy 
number as measured using Alu-gag nested qPCR. (I) Cultures supplemented with 5 mM 
thymidine result in a 14-fold decrease in the fraction of proviral copies that contain uracil 






Figure  3.10  Uracilation  is  independent  of  multiplicity  of  infection  (MOI).  MDMs 
were infected with HIVNL4.3 using MOIs of 0.1, 1 and 10.  (A) The viral gag copy number 
increases with MOI. (B) The MOI does not significantly affect the fraction of viral gag 





























































was assessed by flow cytometry.  Each population was greater than 99% pure. (A) Flow 






Figure 3.12 Three different viral strains show a similar uracilation profile with in 
vitro  infected  MDMs  independent  of  the  differentiation  regimen.  (A)  Only  a  small 
fraction of infected MDMs (HIVSF162) express virally encoded GFP as determined in flow 
cytometry.  (B)  The  kinetics  and  absolute  levels  of  virus  output  as  measured  by  p24 
ELISA is indistinguishable for MDMs infected with HIV SF162 and HIVBAL. (C) Provirus 
copy  number  and  uracil  content  at  dpi  =  3  are  very  similar  in  MDMs  infected  with 
HIVSF162, HIVNL4.3 or HIVBAL (MOI = 0.1).  Proviral copy numbers were measured using 
Alu-gag nested qPCR and the uracil content by Ex Alu-gag nested qPCR. (D) Infection 
of MDMs obtained from peripheral blood monocytes of three donors produces equivalent 
levels of uracilated HIV NL4.3 DNA as judged by ddPCR analysis of the GFP copies. (E) 
The  fraction  of  viral  GFP  copies  that  contain  uracil  is  similar  for  all  three  donors  as 
determined using Ex-ddPCR (ns; not significant). (F) Purified monocytes isolated from 
bulk  PBMCs  were  differentiated  to  MDMs  in vitro using  the  adherence  method,  or  by 
addition of M-CSF or GM-CSF.  The differentiation regimen did not significantly affect 
viral  GFP  expression  in  MDMs  infected  with  HIVSF162,  or  (G)  proviral  DNA  copy 
number as determined by Alu-gag nested qPCR, or (H) the fraction of viral DNA copies 










































































































































































































Figure 3.13 Subcellular fractionation of nuclear and mitochondrial fractions from 
MDMs  resolves  the  two  UNG  isoforms.  Western  blot  analysis  detected  both  the 
mitochondrial (hUNG1) and nuclear (hUNG2) isoforms in MDMs. Cells were 
fractionated  to  isolate  nuclear  and  mitochondrial  fractions  using  the  Qproteome  kit 
(Qiagen).  The  purity  of  the  isolated  fractions  was  confirmed  by  Western  probes  of 











that uracil is only found in HIV DNA isolated from monocytes and not rCD4+ T cells of 
HIV-infected patients.  The shown data are for donor ID 2 (Table S4). For visualization, 
the histograms for the RPP30 Ex-ddPCR data have been down scaled by a factor of ~10 4 
to facilitate comparison with the low abundance pol positive droplets. The insets show 
the raw scatter plots of the pol positive droplets that were used to generate corresponding 
108
histograms for each isolated cell population.  The pol positive droplets for the ddPCR and 
Ex-ddPCR experiments are shown in red and blue, respectively.  The histograms for the 



























Ex-vivo enzyme activity assays  
Protein lysates were obtained using CelLytic M (Sigma) reagent according to the 
manufacturer’s instructions. SAMHD1 activity was determined as previously described 
with several modifications 1. Protein lysates (5 µg) were incubated in buffer containing; 5 
mM [8-3H] dGTP (activator/substrate) (Moravek Biochemicals), 5 mM ATP, and 10 mM 
paranitrophenyl  phosphate  (p-NPP)  in  a  total  volume  of  50  µL.  ATP  was  included  to 
inhibit  nonspecific  phosphatases  and  p-NPP  was  added  to  prevent  the  degradation  of 
dUTP by alkaline phosphatase 2. The small molecule inhibitor (pppCH 2dU) of SAMHD1 
was  used  to  determine  specificity  of  the  assay3.  Reactions  were  incubated  at  37°C  at 
varying  time  points,  at  which  two  microliter  samples  were  removed  and  quenched  by 
spotting  onto  a  C18-reversed  phase  thin  layer  chromatography  (TLC)  plate.    The  TLC 
plate was developed in 50 mM KH2PO4 (pH 4.0) to separate substrate [dGTP (R f = 0.80)] 
from products [dG (R f = 0.20)]. Plates were exposed to a tritium sensitive screen for 5 h 
and then scanned on a Typhoon phosphoimager (GE Healthcare) and the counts present 
in the substrate and product were quantified using the program Quantity One (Bio-Rad).
dUTPase activity was assessed as previously described 4. Briefly, protein lysates 
were incubated with [5- 3H] dUTP (Moravek Biochemicals) and the fraction of substrate 
hydrolyzed to dUMP product was monitored. Reactions were incubated at 37°C for 1 h, 
after which two microliter samples was spotted onto a PEI-cellulose TLC plate. The TLC 
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plates  were  developed  in  0.5  M  LiCl  to  separate  substrate  [dUTP  (Rf  =  0.1)]  from  the 
product [dUMP (R f = 0.6)]. Plates were exposed to a tritium sensitive screen for 5 h and 
scanned on a Typhoon phosphoimager (GE Healthcare).
A  molecular  beacon  hairpin  reporter  assay  was  used  to  determine  endogenous 
UNG  activity  in  crude  cell  extracts4.  Reactions  were  performed  using  5  µg  of  protein 
lysate and 50 nM S-pin-18 in 10 mM Tris-HCl (pH 7.1), 100 mM NaCl, 1 mM EDTA, 
and 0.2% Triton X-100. Supplementing the reaction with the potent Uracil DNA 
glycosylase  inhibitor  (UGI)  showed  no  measurable  activity.  Additionally,  a  molecular 
beacon assay was used to monitor Apurinic/Apyrimidinic endonuclease (APE) activity 5. 
Two FAM and dabcyl quenched DNA duplex substrates were used. A specific substrate 
(SS) containing a single abasic site (Φ) and a non-specific substrate (NS) with the abasic 
site  replaced  with  the  canonical  DNA  base  Thymine  (T).  The  sequence  of  the  specific 
molecular beacon substrate; SS, 5’-FAM-GAGAAΦATAGTCGCG3’ and 5’-
CGCGACTATGTTCTC-dabsyl-3’  (where  Φ  is  a  tetrahydrofuran  abasic  site  analog). 
Independent reactions were performed using 5 µg of protein lysate and 50 nM in 10 mM 
Tris-HCl (pH 7.1), 100 mM NaCl, 1 mM EDTA, and 0.2% Triton X-100. To determine 
APE  activity,  the  difference  in  the  initial  rate  of  the  specific  substrate  from  the  non-
specific  rate  was  measured.    Rates  were  measured  on  a  Fluoro-Max  3  (Horiba  Jobin 
Yvon). 
dNTP Extraction, rNTP removal and LC-MS Quantification 
The quantification of dNTPs from primary immune cells was performed by quantitative 
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LC-MS.  To  remove  the  signal  depression  by  the  abundant  rNTPs 6,  a  boronic  acid 
chromatography  step  was  performed  prior  to  analysis.  Briefly,  NTPs  were  methanol 
extracted  for  1  hr  at  4°C  from  5  million  cells.  Samples  were  supplemented  with 
isotopically  labeled 13C15N-dNTPs  (Sigma-Aldrich)  for  accurate  determination  of  each 
metabolite. Supernatants were dried under vacuum and then resuspended in 50 µL (200 
mM  Ammonium  acetate,  pH  8.8).  This  was  directly  applied  to  100  µL  of  pelleted 
Boronic  Acid  resin  (0.5  mg/mL)  and  incubated  at  4°C  for  1  hr.  Resin  was  pelleted  by 
centrifugation, supernatant removed and dried under vacuum.  Sample was resuspended 
in mobile phase A [2 mM NH4PO4H2, 3 mM Hexylamine (HMA) in dd H2O]. 
Chromatographic separation was performed with an analytical Hypersil Gold C18 
column (100 x 1 mm, 3 µm particle size, Thermo Scientific), using a (Agilent) LC-MS 
system  equipped  with  a  binary  pump.  Mobile  phase  A  was  [2  mM  NH4PO4H2,  3  mM 
Hexylamine  (HMA)  in  dd  H2O]  and  mobile  phase  B  [Acetonitrile].  The  flow  rate  was 
maintained at 50 µL/min and an injection volume of 20 µL. The autosampler was held 
constant at 4°C and the column at 30°C. The chromatographic gradient began at 10 % 
mobile phase, followed by a linear gradient that reached 60 % in 15 min. At the end of 
each run, the column was equilibrated for 10 min. Analyte detection was performed with 
the same LC-MS system with an electrospray ionization source, using multiple-reaction 
monitoring (MRM) analysis in positive ionization mode. The following MRM transitions 
(parent à   product)  were  detected  as  previously  described  with  the  addition  of  dUTP: 
dATP (492 m/z à  136 m/z), dGTP (508 m/z à  152 m/z), dCTP (468 m/z à  112 m/z), 
TTP  (483  m/z à   81  m/z)  and  dUTP  (469  m/z à   81  m/z)7.  A  standard  curve  was 
constructed using equimolar amounts of dNTPs.
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In vitro infection of primary immune cells 
Infections  with  HIV  viral  strains  (NL4.3,  SF162,  BAL)  were  performed  as  previously 
described4. Briefly, primary cells were plated at a density of ~100,000 cells per well in a 
96-well plate. Virus was added to each well and the plate was spin infected for 2 hrs at 
1,200 x g and 30°C and then incubated at 37°C until the given time points. Following 
incubation, cells were collected and stored at -80°C.
Western blots for detection of APOBEC3A and APOBEC3G 
Detection of both APOBEC3A and APOBEC3G was achieved by preparing crude lysates 
as  described  in  Western blots for vpr and vif.  Twenty-five  micrograms  of  each  sample 
was run on an SDS/PAGE gel and transferred to a PVDF membrane. Primary antibody 
(1:1000) was used for detection of APOBEC3G and is cross-reactive with APOBEC3A. 
Membrane  was  incubated  overnight  with  anti-APOBEC3G  C-terminal  29  amino  acid 
obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (cat. no. 
10201;  from  Immunodiagnostics:  Murine  Human  APOBEC3G  (CEM15)  Monoclonal 
Antibody. The secondary HRP-conjugated anti-rabbit IgG (1:2000) was used for 
detection. Global protein expression was assessed by blotting MDM extracts for 
GAPDH.  
Western blots for detection of vif and vpr in mutant viruses 
The  primary  antibody  for  GAPDH  (1:2000)  used  was  a  rabbit  polyclonal  antibody 
(ab15246; Abcam), and the secondary antibody (1:5000) was HRP-conjugated anti-rabbit 
IgG (ab97080; Abcam). Ten micrograms of each sample was run on an SDS/PAGE gel 
and transferred to a PVDF membrane. Detection of virion-associated viral protein R (vpr) 
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was  achieved  using  a  rabbit  polyclonal  antibody  (1:2000)  obtained  through  the  NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH (cat. no.11836; from Dr. Jeffrey 
Kopp)  and  viral  infectivity  factor  (vif)  using  mouse  monoclonal  antibody  (1:2000) 
obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (cat. 
no.  319;  from  Dr.  Michael  H.  Malim)  the  secondary  antibody  (1:5000)  was  HRP-
conjugated  goat  anti-mouse  IgG  (ab97040;  Abcam).  Virion  associated  proteins  were 
probed by re-suspending purified virus directly in buffer containing SDS. For an internal 
control, the same membrane was also blotted for p24 using the mouse monoclonal anti-
p24 (1:2000) primary antibody obtained from the NIH AIDS Reagent Program, Division 
of  AIDS,  NIAID,  NIH  (cat.  no.  24-2;  from  Dr.  Michael  H.  Malim).  The  secondary 
antibody (1:5000) used was an HRP-conjugated goat anti-mouse IgG (ab97040; Abcam). 
Subcellular fractionation of MDM cells 
Isolation  of  mitochondrial  and  nuclear  fractions  was  achieved  using  the  Qproteome 
Mitochondria Isolation kit (37502; Qiagen) according to the manufacturer’s protocol. The 
rabbit polyclonal antibody against the C-terminus of hUNG (62520; Abcam) was used to 
detect  both  mitochondrial  (hUNG1)  and  nuclear  (hUNG2)  isoforms.  To  ensure  equal 
loading  and  transfer,  membranes  were  probed  for  the  mitochondrial  specific  protein 
cytochrome oxidase subunit IV (COXIV) (9715S; Cell Signaling) and nuclear Histone 3 
(H3)  (4850S;  Cell  Signaling).  Immunoreactive  proteins  were  visualized  using  HRP 
linked goat anti-mouse antibody (ab97040; Abcam).   
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Ex-ddPCR method and determination of the fraction of uracil in HIV DNA  
Genomic DNA was first fragmented using the endonuclease BSAJ-1 (1 U) in Cutsmart 
buffer (NEB) for 1 hr at 60°C. Uracil containing DNA sequences were digested using 50 
nM UNG in 1x TMNB+ buffer (10 mM Tris-HCl (pH 8.0) 20 mM NaCl, 11 mM MgCl 2 
and 0.002% Brij-35). Reactions were cleaned up using a MinElute PCR Purification kit 
(Qiagen). UNG or mock digested DNA were diluted in to a PCR master mix containing 
(1x  Platinum  taq  buffer,  1x  droplet  stabilizer  (RainDance),  1  mM  dNTPs,  0.9  µM 
forward and reverse primers, 0.15 µM probe, 2 mM MgCl2, 0.5 µM carboxy-X-
rhodamine (ROX, Sigma) as a passive reference dye, 1 U platinum taq polymerase and 
varying amounts of template DNA) and loaded in to a RainDance source chip 
(RainDance  Technologies).  Different  primer/probe  sets  were  designed  to  tile  the  HIV 
genome to report on heterogeneity of uracil incorporation. Amplification was performed 
with the following thermal program: 95°C for 10 min, followed by 44 cycles of: 95°C for 
15 sec and then 60°C for 1 min, followed by a final step of heating to 95°C for 10 min. 
The final high-temperature cycle cures the droplets. For each step, the ramp cycle time 
was decreased to 0.5 °C/s.  Amplification samples were transferred to a RainDance Sense 
instrument.  Copy numbers of the human RNase P (RPP30) gene were measured in the 
same reaction mixture to determine cell number. DNA isolated from the Jurkat-based cell 
line (J-Lat)8 containing a full-length integrated HIV genome was used to establish gating 
parameters for HIV and RPP30 positive droplets. J-Lat cells were obtained through the 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Clone 
(clone 9846) from Dr. Eric Verdin. Ex-ddPCR data were analyzed using the RainDrop 
Analyst software package (RainDance Technologies). Drop size gating was performed to 
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remove drops of atypical size using a lower and upper size gate boundary for each PMT 
of 800 and 1150, respectively. Intact drops for each of the three clusters (one negative; 
quenched drops, and two positive; PMT1+ and PMT2+) were gated independently using 
the  ellipse-gating  tool.  Gated  clusters  were  spectrally  compensated  using  the  following 
definitions:  (intact  drops/quenched  drops)  as  the  negative  control  for  both  PMT1+  and 
PMT2+, while (intact drops/PMT1+) and (intact drops/PMT2+) were selected for PMT1+ 
and  PMT2+,  respectively.  Positive  cluster  gating  on  spectrally  compensated  data  was 
again achieved by using the ellipse-gating tool. A Poisson correction statistic was applied 
to both positive targets (HIV and RPP30) to remove sampling error 9. Determination of 
uracil free DNA transcripts was determined using Eq 1.
𝐹𝑟𝑎𝑐� !"# = !"#$%$&'()"!*'%# !"#$% !!"#$%$&'()"!*'%# !!"#
!"#$%$&'()"!*'%# !"#$%
             (1) 
Excision sequencing (Ex-seq) library preparation 
Ex-seq  libraries  were  constructed  from  genomic  DNA  by  shearing  for  12  minutes  on 
BioRuptor  (Diagenode),  end  repair,  dA-tailing,  and  adapter  ligation  (NEB)  with  dual 
indexed  adapters  (GSE76091).  Library  concentrations  were  quantitated  with  a  Qubit 
fluorometer  and  mixed  at  equal  proportions  to  yield  500  ng  of  library  DNA.  HIV 
enrichment  was  performed  using  lockdown  probes  designed  against  the  forward  and 
reverse  strand  of  the  HIV  construct  used  for  infection,  HIVNL4.3  (GSE76091).  Briefly, 
libraries were mixed with 5 µg Cot-1 and XGen Blocking oligos and hybridized with the 
lockdown probes at 3 pmol total for 4 hours at 65°C. Probes were isolated on 
Streptavidin  Dynabeads  (M-270;  Invitrogen)  to  capture  HIV  DNA  using  Nimblegen 
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SeqCap  EZ  Hybridization  and  Wash  kit  as  indicated  in  the  XGen  lockdown  probe 
protocol.  DNA  was  eluted  in  water  and  samples  were  split  in  half,  followed  by  uracil 
removal in one sample with UNG (5 U) and T4 Endonuclease IV (10 U) digestion for 2 
hours at 37°C on beads. On-bead PCR was performed for 22 cycles with short Illumina 
primers  (GSE76091)  and  Maxima  Taq  DNA  polymerase  (Invitrogen).  PCR  products 
were purified with 1.9x volumes of Ampure XP beads (Agencourt) and quantified with a 
Qubit fluorometer. Forward and reverse lockdown reactions were pooled for UNG- and 
UNG+ independently and two lanes of Illumina HiSeq were performed. Data files from 
this study have been deposited to the NCBI Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) under accession GSE76091.
Excision-seq data analysis 
Demultiplexed FASTQ records were trimmed to remove low quality cycles (cycles 1 and 
2,  and  70-125  for  HT29  samples),  and  processed  records  were  aligned  to  the  human 
(hg19) and HIV reference (HIV NL4.3) with bwa mem (unpublished). Alignments in BAM 
format were converted to bedGraph coverage with BEDTools. Samples were 
deduplicated with samtools rmdup and Piccard markduplicates. VCF files were generated 
for mutation analysis from the rmdup files with freebayes and filtered with vcffilter for 
quality scores greater than 4010. Mutations were further filtered for a depth of greater than 
10  reads  and  10  or  more  unique  sequencing  start  sites.  Chimeric  and  discordant  reads 
were  identified  with  samtools  and  were  normalized  to  counts  per  million  reads  that 
mapped  to  HIV.  A  reproducible  software  pipeline  for  analysis  of  Excision-seq  data  is 
available at https://github.com/hesselberthlab/stivers-hiv. 
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Ex-Alu-gag nested PCR for uracil detection 
Ex-Alu-gag nested  PCR  begins  with  the  first  amplification  (40  cycles)  used  a  primer 
complementary to genomic Alu sequences and a gag primer and ~100 ng genomic DNA. 
In addition to samples, reactions containing: gag primer only, no-template, and genomic 
DNA isolated from uninfected matched cells were used as controls. A standard curve for 
Ex-Alu-gag nested qPCR was generated using DNA isolated from J-Lat cells.  Although 
there  is  some  debate  concerning  the  measurement  of  absolute  proviral  copy  numbers 
using  Alu-gag  nested  qPCR,  Ex-Alu-gag  nested  qPCR  is  unambiguous  with  respect  to 
determining the change in copy number resulting from UNG digestion.  This is due to the 
fact  that  identical  DNA  samples  are  used  for  the  PCR  amplification  steps.    Thus  the 
fraction of the proviral population that contains uracil within the gag amplicon may be 
reliably measured. 
Cytokine stimulation of cultured MDMs  
FACS sorted (GFP-/+) MDM populations were maintained in culture media for indicated 
times prior to cytokine stimulation. MDMs were either stimulated by co-culture with the 
IFNγ (50 ng/mL, R&D Systems) and 200 ng HIV tat peptide (ProSpec Ltd.) or IL-4 (50 
ng/mL,  R&D  Systems).  At  three  days  post-stimulation  (dps),  the  cytokine  containing 
media  is  removed  and  replaced  with  fresh  culture  media.  Viral  supernatants  were 
collected at varying time points from each well and assayed for HIV-1 p24 production 
using a sensitive ELISA (Alliance HIV-1 p24 antigen ELISA kit, Perkin Elmer). 
Isolation of primary cells from donor PBMCs 
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Peripheral  blood  mononuclear  cells  (PBMCs)  were  isolated  from  HIV-1  positive  or 
negative  donors  using  density  centrifugation  on  a  Ficoll-Hypaque  gradient.  Monocytes 
were isolated from the PBMC population using the Pan monocyte Isolation Kit (Miltenyi 
Biotec).  Monocytes  were  differentiated  into  macrophages  over  7  days  using  MDM-20 
media containing RPMI 1640, 20% (vol/vol) autologous plasma, 10 ng/mL GM-CSF or 
M-CSF (BD Biosciences), 1× HEPES, and 1× Glutamine (Gibco). Cultured MDMs were 
maintained in media containing RPMI 1640 + 10% (vol/vol) dialyzed FBS, 1% 
Pen/Strep. CD4+ T cells were isolated from PBMC population using the CD4+ isolation 
kit (CD4+ T cell Isolation kit II, Miltenyi Biotec). CD4+ cells were activated with 0.5 
µg/mL phytohemagglutinin (PHA) for 3 days in IL-2 containing media. Resting CD4+ 
cells  were  further  enriched  from  the  bulk  CD4+  cell  population  by  negative  selection 
against biotinylated activation markers; CD25, CD69 and HLA-DR (Miltenyi Biotec). 
Purity of isolated cell populations  
The  purity  of  monocytes,  activated  and  resting  CD4+  cells  was  determined  by  flow 
cytometry  with  fluorescent  labeling  of  anti-human;  Fluorescein  isothiocyanate  (FITC)- 
and  allophycocyanin  (APC)-conjugated  mAbs  CD4,  CD25,  CD69  and  HLA-DR  (BD 
Biosciences). Isotype-matched control mAbs (BD Biosciences) were used for gating and 
quantification. Monocyte and MDM populations were stained using brilliant violet 421-
conjugated  (BV421)  anti-CD14,  CD16-APC  and  CD3-FITC.  The  purity  of  these  cells 
were analyzed by flow cytometry using a FACS Canto II (BD Biosciences) and FlowJo 
software (Treestar). Using this method we obtained monocytes with a purity of >99.9% 
with  undetectable  T  cell  contamination.  Cells  were  then  pelleted  and  used  for  protein 
extraction,  dNTP  extraction,  or  infection  as  described  above;  for  cell  infections,  cells 
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were analyzed for GFP expression by FACS analysis. 
In vitro infection and nested limiting dilution DNA sequencing of CD4+ T cells 
T cells were infected with replication-competent HIV BAL as previously described above. 
The HIV BAL (R5) virus was obtained through NIH AIDS Reagent Program, Division of 
AIDS,  NIAID,  NIH  (cat.  no.  510;  contributors:  Dr.  Suzanne  Gartner,  Dr.  Mikulas 
Popovic and Dr. Robert Gallo). Briefly, CD4+ T cells isolated from PBMCs of an HIV-1 
negative donor were purified using a negative selection method (CD4 + T cell Isolation 
Kit II, Miltenyi Biotec) and activated with PHA for 3 days in IL-2-containing medium. A 
spinoculation method (2 hrs, 37°C, 1200 x g) was used to infect activated CD4+ T cells 
with replication-competent HIVBaL virus (300 ng p24/106 cells). Following incubation for 
6 days in IL-2 containing media, supernatants were collected and stored at -80°C. Freshly 
isolated  CD4+  T  cells  were  activated  by  αCD3/αCD28  stimulation  for  3  days  in  IL-2 
containing medium and then plated (100 µL/well) into a 96-well v-bottom plate. HIV BaL 
(500 ng p24/10 6 cells) was added to each well and cells were infected by spinoculation. 
Following infection, cells were suspended in 40mL of IL-2 containing medium 
supplemented with enfuvirtide (10 µM) to prevent additional rounds of viral replication. 
Following a two day incubation at 37°C, genomic DNA was extracted from 10 7 CD4 + 
cells  using  the  Qiagen  Gentra  Purgene  Cell  Kit  A.  DNA  was  subjected  to  a  nested 
limiting dilution PCR protocol adapted from Ho et al. with the following modifications: 
30 cycles were run for the outer PCR, 40 cycles were run for each inner PCR, and all 
clonal outer wells were subjected to the 4 inner PCRs (A-D; corresponding to gag, pol, 
rev and env regions) regardless if positive or negative for the gag inner PCR11.
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Extracellular viral RNA limiting dilution sequencing  
HIV infected (HIVSF162) MDMs were sorted into GFP – and GFP+ populations and diluted 
serially in 5-fold increments (1x10 5 – 100 cells) using 12-well plates (Costar). Cells were 
maintained in culture for 14 days prior to cytokine simulation and supernatant collection. 
Extracellular  viral  RNA  was  collected  from  the  supernatants  of  individual  wells  that 
contained the fewest number of input cells and were p24-positive in an attempt to obtain 
virus  released  from  a  cell  containing  a  single  provirus.  Extracellular  viral  RNA  was 
purified  using  a  ZR-96  Viral  RNA  Kit  (Zymo  Research).  Isolated  viral  RNAs  were 
DNase-treated (Life Technologies) and reverse transcribed using a qScript cDNA 
synthesis  kit  (Quanta  Biosciences)  according  to  the  manufacturer’s  protocol.  Using  the 
products  of  RT-PCR,  nested  PCR  reactions  were  used  to  amplify  the  LTR  and  env 
regions of interest (primer sequences are listed in Table S3). Limiting dilution PCR was 
performed using Platinum Taq High-Fidelity polymerase (Invitrogen). For LTR 
amplification, outer primers 5LTROut and mod_VQA_R and inner primers 5LTRIn and 
mod_VQA_R were used. Thermocycler settings were the same for both outer and inner 
LTR PCR reactions: 94°C for 2 min, followed by 29 cycles of: 94°C for 15 sec, 55°C for 
30 sec and then 68°C for 1 min, followed by a final extension at 68°C for 7 min. For env 
amplification,  outer  primers  ES7  and  ES8  and  inner  primers  Nesty8  and  DLoop  were 
used. Thermocycler settings were the same for both outer and inner env PCR reactions: 
94°C for 3 min, followed by 25 cycles of: 94°C for 30 sec, 55°C for 30 sec and then 68°C 
for 1 min, followed by a final extension at 68°C for 5min.  
cDNA  was  diluted  (1/20  –  1/1000)  and  used  as  input  for  the  outer  PCR  reaction. 
Aliquots (1µL) from each outer PCR product were used as input for inner PCR reactions 
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and  subjected  to  1%  agarose  gel  electrophoresis.  Inner  clonal  PCR  reactions  from 
selected dilutions were used to identify dilutions where <20% of the PCR reactions were 
positive, where the corresponding outer PCR dilution contained one template with >90% 
of possibility by Poisson statistics. PCR products were gel extracted using the QIAquick 
Gel Extraction Kit (Qiagen) and directly sequenced (Sanger) without cloning (Genewiz). 
Forward and reverse sequences for each sample were aligned into one consensus contig 
per sample using default assembly parameters with CodonCode Sequence assembly and 
Alignment software and aligned to HIVSF162 reference sequence. Chromatograms 
showing double peaks were taken as evidence for more than one template present in the 
initial PCR reaction and were discarded from further analysis.  
Bronchio-alveolar lavage (BAL) cell processing 
Bronchoscopy  and  broncho-alveolar  lavage  was  performed  on  a  single  HIV-1  infected 
patient pre and post-ART treatment. At the time of the first bronchoscopy the patient was 
ART  naïve  with  recent  plasma  viral  load  24,162  copies/ml  and  CD4  459  cells/mm3. 
Second  bronchoscopy  occurred  9.2  months  later,  after  6  months  of  ART  treatment 
(efaviernz/emtricitabine/tenofovir)  with  plasma  viral  load  <20  copies/ml  and  CD4  413 
cells/mm3. To obtain alveolar macrophages (AMs), bronchoscopy and lavage were done, 
as described elsewhere12. Briefly, lavage fluid was collected, filtered and BAL cells were 
pelleted  by  centrifugation.  BAL  cells  were  washed  with  HBSS  and  counted.  After 
centrifugation, cells were re-suspended in Recovery Cell Culture freezing media 
according to the BAL count (10 6 cells/mL) and stored in a -140°C freezer. PBMCs were 
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isolated  on  a  ficoll-hypaque  gradient  and  were  processed  in  the  same  manner  as  BAL 
cells. 
Determination of HIV pol copies and uracilation in in vivo infected monocytes and 
resting T cells using ddPCR and Ex-ddPCR 
Monocytes  and  resting  CD4+  T  cells  purified  via  negative  selection  (Miltenyi  Biotec) 
from blood collected from six HIV infected patients on antiretroviral therapy (ART). Cell 
purity was determined as described above in Purity of isolated cell populations. Cellular 
DNA was extracted using a QIamp DNA Midi Kit (Qiagen) following the manufacturer’s 
protocol.  The  frequency  of  total  HIV  DNA  (pol  copies/106  cells)  was  determined  by 
ddPCR using published primers to conserved regions of HIV pol (Althaus, 2010) and the 
reference cellular gene RNase P (RPP30) for genomic quantification. Total cellular DNA 
was  estimated  by  halving  the  number  of  RPP30  copies  and  HIV  copy  numbers  per 
diploid  cell  were  calculated  as  the  ratio  of  template  pol  copies  per  diploid  cell  (pol 
copies/106 cells). Due to the low frequency of HIV DNA in a large background of host 
cellular  DNA  it  was  desirable  to  load  as  much  total  DNA  (~106  cells)  as  possible  to 
maximize assay sensitivity. See Fig. S10 for further details.  
The  limit  of  detection  and  quantification  of  the  ddPCR  assay  was  evaluated  by 
establishing  the  loading  limit  and  intrinsic  limit  of  detection.  A  dilution  series  of 
uninfected PBMC DNA was used to determine the maximum amount of total DNA that 
could be accurately measured in a single ddPCR reaction. Cellular RPP30 was used to 
monitor  input  DNA  and  showed  a  linear  response  across  a  wide  range  (103-106)  of 
RPP30 copies. The intrinsic limit of detection of (5 copies/10 6 cells) was determined by 
serially  diluting  DNA  from  infected  CD4+  T  cells  into  a  background  of  healthy  donor 
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PBMC DNA (250,000 cells). For patient samples, replicate measurements were taken to 














Uracils do not arise from APOBEC cytosine deamination 
It has been previously reported that MDMs do not express high levels of APOBEC3G 
(A3G)  or  APOBEC3A  (A3A)  DNA  cytidine  deaminases,  and  that  the  limited  levels 
present reside in the inactive high-molecular weight (HMW) form 13,14.  Nevertheless, we 
wanted to completely exclude the possibility that the detected uracils arose significantly 
from APOBEC cytosine deamination. 
Since viral vif protein is known to target A3G for proteasomal degradation, we 
reasoned  that  the  viral  DNA  products  produced  from  a  vif  deletion  virus  should  have 
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increased  uracilation  levels  due  to  increased  APOBEC  activity.    Although  vif  serves 
other functions that promote infection of MDMs 15, which would be expected to result in 
lower overall levels of infectivity upon its deletion, these effects would not change the 
uracil content of viral DNA products.  Accordingly, we infected MDMs with wild-type 
HIVNL4.3 virus  or  the  vif  deletion  mutant,  HIVNL4.3(Δvif),  which  contains  no  detectable 
packaged vif protein (Fig. S3A).  Infection of MDMs with these viruses produced only 
small changes in the basal level of A3G in cell extracts, possibly due to the resistance of 
HMW-A3G  to  vif  (Fig.  S3B).    Similarly,  minor  decreases  in  the  already  low  basal 
expression  levels  of  A3G  and  A3A  were  observed  in  cell  extracts  obtained  before  and 
after infection with the replication competent HIVSF162 virus (Fig. S3C).  
In contrast with the small effects on A3G and A3A levels, HIV NL4.3(Δvif) showed 
a  4-fold  decrease  in  GFP  expression  as  compared  to  wild-type  virus  at  one  day  post-
infection (Fig. S3D).  Although infections with the Δvif virus produced the same levels of 
early DNA products as wild-type (Fig. S3E), proviral DNA appeared at a much lower 
level  as  judged  by  Alu-gag  nested  qPCR  (Fig.  S3E).    Importantly,  no  increases  in  the 
uracilation  level  of  early  viral  DNA  products  or  proviral  DNA  were  observed  upon 
infection with HIVNL4.3(Δvif) (Fig. S3F). 
If the viral uracils in MDMs arose from dUTP incorporation, we anticipated that 
the addition of thymidine to the culture media prior to infection would lead to an increase 
in  the  viral  copy  number  (less  uracil  related  pre-integration  restriction)  and  less  uracil 
present in proviral DNA due to increased competition by TTP during reverse 
transcription (Fig. S3G, 3H, 3I). Although the presence of 5 mM thymidine produced no 
significant change in GFP expression (Fig. 3G), it increased the proviral copy number by 
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5-fold (Fig. 3H), and decreased the uracilation level of proviral DNA by 14-fold (Fig. 
3I).    The  combined  results  strongly  support  the  conclusion  that  the  viral  uracils  arise 


















































































None 20 6,160 3 2 2 0
IFNγ 27 8,316 2 0 0 0
IL-4 32 9,856 2 0 0 0
        
 
env
None 8 3,264 0 0 0 0
IFNγ 14 5,712 0 0 0 0








None 23 7,084 0 0 0 0
IFNγ 21 6,468 0 0 0 0
IL-4 15 4,620 0 0 0 0
        
 
env
None 19 7,752 0 0 0 0
IFNγ 17 6,936 0 0 0 0
IL-4 16 6,528 0 0 0 0
 
T cells LTR None 14 4312 39 5 2 0
env None 14 5712 50 5 1 0
aInfected MDMs containing proviruses were sorted into two populations according to GFP 
fluorescence  at  14  days  post  infection  and  then  activated  with  the  indicated  cytokines.  Mutation 
frequencies are calculated based on total nucleotides sequenced (i.e. frequency = mutated nucleotide 
count/total nucleotides). bIn vitro infected resting CD4+ T cells. cInsertion and deletions counted on a 









Table 1.2 (Cont.) Mutational analysis of proviral DNA isolated from MDMs and 
CD4+ T cells 
 
Table S2 (cont.) Mutational analysis of extracellular viral RNA produced from 

























Noned 5 1,540 0 0 0 0
IFNγ 5 1,540 0 0 0 0
IL-4 14 4,312 0 0 0 0
        
 
env
Nonec 10 4,080 48 7 0 3
IFNγ 6 2,448 56 9 3 7
IL-4 8 3,264 2 0 0 0







None 7 2,156 0 0 0 0
IFNγ 7 2,156 0 0 0 0
IL-4 7 2,156 0 0 0 0
        
 
env
None 11 4,488 0 0 0 0
IFNγ 9 3,672 0 0 0 0
IL-4 9 3,672 0 0 0 0
aInfected MDMs containing proviruses were sorted into two populations according to GFP 
fluorescence  at  14  days  post  infection  and  then  activated  with  the  indicated  cytokines.  Mutation 
frequencies are calculated based on total nucleotides sequenced (i.e. frequency = mutated nucleotide 
count/total nucleotides). RT-PCR was used to amplify extracellular viral RNAs into cDNA prior to 
clonal sequencing.
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Table S3. Primer and molecular beacon probe sequences (5’à 3’)
GFP forward CGACTTCTTCAAGTCCGCCA
GFP reverse (79bp) CTTGTAGTTGCCGTCGTCCT
GFP reverse (281bp) TGCCGTCCTCGATGTTGTG
GFP reverse (363bp) CTCAGGTAGTGGTTGTCGGG






gag forward (6F) CATGTTTTCAGCATTATCAGAAGGA




LRT forward (MH531) TGTGTGCCCGTCTGTTGTGT
LRT reverse (MH532) GAGTCCTGCGTCGAGAGATC
LRT probe FAM-CAGTGGCGCCCGAACAGGGA-BHQ2
2LTR forward (MH535) AACTAGGGAACCCACTGCTTAAG




pol forward (mf299) GCACTTTAAATTTTCCCATTAGTCCTA
pol reverse (mf302) CAAATTTCTACTAATGCTTTTATTTTTTC
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